This bibliography shows the most interesting papers selected from pmc PubMedCentral which were newly included in covid028V
It is available online and for download at http://www.kidney.de/write/PMCmedVIP_covid028V.html
Skewed: Nephrology, Rheumatology, Immunology, Cell Biology, Research Methods. on-topic and educational Clinical Medicine.
The full table of all monthly collections is: at house-of-papers.com
PMC searches were done at moremed.org

{{tp|p=34117206|t=2021. A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine.|pdf=|usr=}}
{{tp|p=34171719|t=2021. Cardiac arrest secondary to Covid19 pneumonia post full vaccination.|pdf=|usr=}}
{{tp|p=34133027|t=2021. Cerebral venous thrombosis post BNT162b2 mRNA SARS-CoV-2 vaccination: A black swan event.|pdf=|usr=}}
{{tp|p=34185336|t=2021. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.|pdf=|usr=}}
{{tp|p=34112654|t=2021. Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'.|pdf=|usr=}}
{{tp|p=34133951|t=2021. Seroconversion rates following COVID-19 vaccination among patients with cancer.|pdf=|usr=}}
{{tp|p=34142647|t=2021. Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021.|pdf=|usr=}}
{{tp|p=34172912|t=2021. Orofacial adverse effects of COVID-19 vaccines exist but are rare.|pdf=|usr=}}
{{tp|p=34108961|t=2021. Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model.|pdf=|usr=}}
{{tp|p=34093567|t=2021. COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says.|pdf=|usr=}}
{{tp|p=34123969|t=2021. Mandatory Infant Vaccinations in France During the COVID-19 Pandemic in 2020.|pdf=|usr=}}
{{tp|p=34109900|t=2021. SARS-CoV-2: Unique Challenges of the Virus and Vaccines.|pdf=|usr=}}
{{tp|p=34162141|t=2021. An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.|pdf=|usr=}}
{{tp|p=34138513|t=2021. Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia.|pdf=|usr=}}
{{tp|p=34155756|t=2021. Medical Oncology Group of Australia position statement: COVID-19 vaccination in patients with solid tumours.|pdf=|usr=}}
{{tp|p=34174156|t=2021. Hyaluronic acid soft tissue filler delayed inflammatory reaction following COVID-19 vaccination - A case report.|pdf=|usr=}}
{{tp|p=34167874|t=2021. Clinical and histopathological views of morbilliform rash after COVID-19 mRNA vaccination mimic those in SARS-CoV-2 virus infection-associated cutaneous manifestations.|pdf=|usr=}}
{{tp|p=34143368|t=2021. Minimal change disease following vaccination for SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34182207|t=2021. A case of longitudinally extensive transverse myelitis following vaccination against Covid-19.|pdf=|usr=}}
{{tp|p=34153802|t=2021. New-onset refractory status epilepticus following the ChAdOx1 nCoV-19 vaccine.|pdf=|usr=}}
{{tp|p=34115170|t=2021. First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34120504|t=2021. COVID Arm: Delayed Hypersensitivity Reactions to SARS-CoV-2 Vaccines Misdiagnosed as Cellulitis.|pdf=|usr=}}
{{tp|p=34171649|t=2021. Vaccine-Induced Immune Thrombotic Thrombocytopenia with Disseminated Intravascular Coagulation and Death following the ChAdOx1 nCoV-19 Vaccine.|pdf=|usr=}}
{{tp|p=34111775|t=2021. Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine.|pdf=|usr=}}
{{tp|p=34170306|t=2021. Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada.|pdf=|usr=}}
{{tp|p=34146600|t=2021. Histologic correlates of gross hematuria following Moderna COVID-19 vaccine in patients with IgA nephropathy.|pdf=|usr=}}
{{tp|p=34119512|t=2021. Relapse of minimal change disease following the AstraZeneca COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34119511|t=2021. Anti-GBM nephritis with mesangial IgA deposits after SARS-CoV-2 mRNA vaccination.|pdf=|usr=}}
{{tp|p=34116086|t=2021. Relapse of IgG4-related nephritis following mRNA COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34124415|t=2021. Humoral Response to SARS-CoV-2 in Hemodialysis Patients.|pdf=|usr=}}
{{tp|p=34179593|t=2021. Letter regarding: "A Case of Gross Hematuria and IgA Nephropathy Flare-Up Following SARS-CoV-2 Vaccination".|pdf=|usr=}}
{{tp|p=34130372|t=2021. COVID-19 vaccine-induced acute generalized exanthematous pustulosis.|pdf=|usr=}}
{{tp|p=34126043|t=2021. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban.|pdf=|usr=}}
{{tp|p=34181881|t=2021. Heterologous vaccine regimens against COVID-19.|pdf=|usr=}}
{{tp|p=34181880|t=2021. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.|pdf=|usr=}}
{{tp|p=34119034|t=2021. SARS-CoV-2 vaccination for patients with inflammatory bowel disease.|pdf=|usr=}}
{{tp|p=34119033|t=2021. SARS-CoV-2 vaccination for patients with inflammatory bowel disease - Authors' reply.|pdf=|usr=}}
{{tp|p=34115963|t=2021. Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccination.|pdf=|usr=}}
{{tp|p=34173610|t=2020. COVID-19 Vaccines A Global Common Good.|pdf=|usr=}}
{{tp|p=34153265|t=2021. SARS-CoV-2 vaccination in people with HIV.|pdf=|usr=}}
{{tp|p=34153264|t=2021. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.|pdf=|usr=}}
{{tp|p=34111410|t=2021. Bell's palsy and SARS-CoV-2 vaccines-an unfolding story - Authors' reply.|pdf=|usr=}}
{{tp|p=34111409|t=2021. Bell's palsy and SARS-CoV-2 vaccines-an unfolding story.|pdf=|usr=}}
{{tp|p=34174193|t=2021. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.|pdf=|usr=}}
{{tp|p=34174192|t=2021. Single-dose SARS-CoV-2 vaccination efficacy in the elderly.|pdf=|usr=}}
{{tp|p=34174190|t=2021. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study.|pdf=|usr=}}
{{tp|p=34147141|t=2021. COVID-19 vaccination in patients with alpha1-antitrypsin deficiency.|pdf=|usr=}}
{{tp|p=34179831|t=2021. Adverse events after first COVID-19 vaccination in patients with autoimmune diseases.|pdf=|usr=}}
{{tp|p=34140165|t=2021. Enfermedades autoinmunes y vacunas contra la COVID-19. Toma de decisiones en escenarios de incertidumbre.|pdf=|usr=}}
{{tp|p=34119341|t=2021. Eficacia y seguridad de la vacuna frente a SARS-CoV-2 en pacientes con arteritis de celulas gigantes.|pdf=|usr=}}
{{tp|p=34119340|t=2021. Penfigoide ampolloso y vacuna COVID-19.|pdf=|usr=}}
{{tp|p=34119339|t=2021. Vacunas COVID-19 e infeccion por herpes.|pdf=|usr=}}
{{tp|p=34133864|t=2021. mRNA Covid-19 Vaccines in Pregnant Women.|pdf=|usr=}}
{{tp|p=34143345|t=2021. Headache after COVID-19 vaccination: updated report from the Italian Medicines Agency database.|pdf=|usr=}}
{{tp|p=34128150|t=2021. Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab.|pdf=|usr=}}
{{tp|p=34138444|t=2021. Expert Consensus and Narrative Review on the Management of Multiple Sclerosis in the Arabian Gulf in the COVID-19 Era: Focus on Disease-Modifying Therapies and Vaccination Against COVID-19.|pdf=|usr=}}
{{tp|p=34117994|t=2021. Emerging Infection, Vaccination, and Guillain-Barre Syndrome: A Review.|pdf=|usr=}}
{{tp|p=34155481|t=2021. Emerging issues related to COVID-19 vaccination in patients with cancer.|pdf=|usr=}}
{{tp|p=34137014|t=2021. Emerging issues related to COVID-19 vaccination in patients with cancer.|pdf=|usr=}}
{{tp|p=34162739|t=2021. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.|pdf=|usr=}}
{{tp|p=34184708|t=2021. Consolidado de recomendaciones del Comite Asesor de Vacunas y Estrategias de Inmunizacion-CAVEI, sobre priorizacion de vacunacion COVID-19.|pdf=|usr=}}
{{tp|p=34149145|t=2021. Pericarditis tras la administracion de la vacuna de ARNm BNT162b2 contra la COVID-19.|pdf=|usr=}}
{{tp|p=34120531|t=2021. COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A review of the potential mechanisms and proposed management.|pdf=|usr=}}
{{tp|p=34120357|t=2021. Exact sequential test for clinical trials and post-market drug and vaccine safety surveillance with Poisson and binary data.|pdf=|usr=}}
{{tp|p=34158837|t=2021. Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.|pdf=|usr=}}
{{tp|p=34076943|t=2021. Clinical consequences of the suboptimal effect of messenger RNA-based SARS-CoV-2 vaccine in renal transplant recipients.|pdf=|usr=}}
{{tp|p=34119319|t=2021. Evaluation of Covid-19 vaccines: Pharmacoepidemiological aspects.|pdf=|usr=}}
{{tp|p=34119317|t=2021. COVID-19 vaccines: A perspective from social pharmacology.|pdf=|usr=}}
{{tp|p=34132881|t=2021. Beeinflusst Methotrexat die Wirksamkeit der Impfung gegen SARS-CoV-2?|pdf=|usr=}}
{{tp|p=34114269|t=2021. Guillain-Barre Syndrome Variant Occurring after SARS-CoV-2 Vaccination.|pdf=|usr=}}
{{tp|p=34114256|t=2021. Guillain-Barre Syndrome following ChAdOx1-S/nCoV-19 Vaccine.|pdf=|usr=}}
{{tp|p=34167947|t=2021. Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response.|pdf=|usr=}}
{{tp|p=34158370|t=2021. Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City.|pdf=|usr=}}
{{tp|p=34172502|t=2021. Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis.|pdf=|usr=}}
{{tp|p=34114220|t=2021. Correspondence in reference to the previously published Epub manuscript: immune thrombocytopenic purpura after SARS-CoV-2 vaccine.|pdf=|usr=}}
{{tp|p=34171971|t=2021. Maternal and Child Symptoms Following COVID-19 Vaccination Among Breastfeeding Mothers.|pdf=|usr=}}
{{tp|p=34145995|t=2021. Chimeric Virus-like Particles of Universal Antigen Epitopes of Coronavirus and Phage Qbeta Coat Protein Trigger the Production of Neutralizing Antibodies.|pdf=|usr=}}
{{tp|p=34180347|t=2021. COVID-19 vaccines: concerns beyond protective efficacy and safety.|pdf=|usr=}}
{{tp|p=34176415|t=2021. COVID-19 vaccines and thrombosis with thrombocytopenia syndrome.|pdf=|usr=}}
{{tp|p=34105432|t=2021. Forty days of regulatory emergency use authorisation of COVID-19 vaccines: Interfacing efficacy, hesitancy and SDG target 3.8.|pdf=|usr=}}
{{tp|p=34162139|t=2021. Regulatory T cells and vaccine effectiveness in older adults. Challenges and prospects.|pdf=|usr=}}
{{tp|p=34120553|t=2021. Tinnitus following COVID-19 vaccination: report of three cases.|pdf=|usr=}}
{{tp|p=34127187|t=2021. COVID-19: Bergamo effect and vaccination strategy.|pdf=|usr=}}
{{tp|p=34127186|t=2021. COVID-19: Effect-modelling of vaccination in Germany with regard to the mutant strain B.1.1.7 and occupancy of ICU facilities.|pdf=|usr=}}
{{tp|p=34110010|t=2021. Pityriasis rosea after mRNA COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34118064|t=2021. A forecast of maternal deaths with and without vaccination of pregnant women against COVID-19 in Mexico.|pdf=|usr=}}
{{tp|p=34115887|t=2021. Maternal and neonatal SARS-CoV-2 antibodies assessment after mRNA maternal vaccination in the third trimester of pregnancy.|pdf=|usr=}}
{{tp|p=34105336|t=2021. Anaphylaxis is a rare reaction in COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34145459|t=2021. Large-Scale Identification of T-Cell Epitopes Derived From Severe Acute Respiratory Syndrome Coronavirus 2 for the Development of Peptide Vaccines Against Coronavirus Disease 2019.|pdf=|usr=}}
{{tp|p=34175640|t=2021. Acute Ischemic Stroke Revealing ChAdOx1 nCov-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia: Impact on Recanalization Strategy.|pdf=|usr=}}
{{tp|p=34137808|t=2021. Sperm Parameters Before and After COVID-19 mRNA Vaccination.|pdf=|usr=}}
{{tp|p=34160567|t=2021. The Search for a Single Vaccine Against Coronaviruses Yet to Come.|pdf=|usr=}}
{{tp|p=34106201|t=2021. Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar.|pdf=|usr=}}
{{tp|p=34185047|t=2021. Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=34185046|t=2021. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34185045|t=2021. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military.|pdf=|usr=}}
{{tp|p=34100306|t=2021. Late-onset cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine in an immunocompromised patient.|pdf=|usr=}}
{{tp|p=34161714|t=2021. Audio Interview: A New mRNA Vaccine.|pdf=|usr=}}
{{tp|p=34133867|t=2021. Spike D614G - A Candidate Vaccine Antigen Against Covid-19.|pdf=|usr=}}
{{tp|p=34110115|t=2021. SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia.|pdf=|usr=}}
{{tp|p=34107187|t=2021. Audio Interview: Treating Complications of Covid Vaccination.|pdf=|usr=}}
{{tp|p=34133853|t=2021. Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. Reply.|pdf=|usr=}}
{{tp|p=34133852|t=2021. Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.|pdf=|usr=}}
{{tp|p=34133851|t=2021. Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.|pdf=|usr=}}
{{tp|p=34107179|t=2021. Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. Reply.|pdf=|usr=}}
{{tp|p=34107178|t=2021. Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.|pdf=|usr=}}
{{tp|p=34182569|t=2021. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses.|pdf=|usr=}}
{{tp|p=34142152|t=2021. COVID-19 vaccination and dialysis patients: why the variable response.|pdf=|usr=}}
{{tp|p=34117884|t=2021. Correspondence: Breakthrough COVID-19 Infections among Health Care Workers after Two Doses of ChAdOx1 nCoV-19 Vaccine.|pdf=|usr=}}
{{tp|p=34161019|t=2021. "Vaccins contre la Covid-19 disponibles en Europe".|pdf=|usr=}}
{{tp|p=34160997|t=2021. "A propos de l'article Vaccins contre la Covid-19 disponibles en Europe la Covid-19 disponibles en Europe".|pdf=|usr=}}
{{tp|p=34160995|t=2021. Covid-19 : la course d'obstacles vaccinale.|pdf=|usr=}}

{{tp|p=34100150|t=2021. Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization.|pdf=|usr=}}
{{tp|p=34133825|t=2021. Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report.|pdf=|usr=}}
{{tp|p=34171116|t=2021. Por una priorizacion de las personas con trastornos adictivos en la vacunacion frente a la COVID-19.|pdf=|usr=}}
{{tp|p=34176237|t=2021. Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative.|pdf=|usr=}}
{{tp|p=34094633|t=2021. All Nations Must Prioritize the COVID-19 Vaccination Program for Elderly Adults Urgently.|pdf=|usr=}}
{{tp|p=34128562|t=2021. COVID-19 vaccine anaphylaxis: PEG or not?|pdf=|usr=}}
{{tp|p=34128561|t=2021. COVID-19 vaccine anaphylaxis: IgE, complement or what else? A reply to: "COVID-19 vaccine anaphylaxis: PEG or not?"|pdf=|usr=}}
{{tp|p=34128559|t=2021. Other excipients than PEG might cause serious hypersensitivity reactions in COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=34185824|t=2021. Perspectives on COVID-19 vaccination among kidney and pancreas transplant recipients living in New York City.|pdf=|usr=}}
{{tp|p=34175364|t=2021. Asymptomatic SARS-CoV-2 infection following first dose mRNA-1273 COVID-19 vaccine in a veterans affairs long term care facility.|pdf=|usr=}}
{{tp|p=34182049|t=2021. De Novo and Relapsing Glomerular Diseases After COVID-19 Vaccination: What Do We Know So Far?|pdf=|usr=}}
{{tp|p=34174364|t=2021. Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients.|pdf=|usr=}}
{{tp|p=34118200|t=2021. Adverse effects of COVID-19 messenger RNA vaccines among pregnant women: a cross-sectional study on healthcare workers with detailed self-reported symptoms.|pdf=|usr=}}
{{tp|p=34151047|t=2021. Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine.|pdf=|usr=}}
{{tp|p=34156871|t=2021. The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in Kappa18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells.|pdf=|usr=}}
{{tp|p=34109031|t=2021. SARS-CoV-2 Brazil variants in Latin America: More serious research urgently needed on public health and vaccine protection.|pdf=|usr=}}
{{tp|p=34099378|t=2021. Coronavirus disease vaccination in heart failure: No time to waste.|pdf=|usr=}}
{{tp|p=34155020|t=2021. Trigeminal and cervical radiculitis after tozinameran vaccination against COVID-19.|pdf=|usr=}}
{{tp|p=34135077|t=2021. ChAdOx1 nCOV-19 vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis (CVST).|pdf=|usr=}}
{{tp|p=34149203|t=2021. Fractal-fractional order mathematical vaccine model of COVID-19 under non-singular kernel.|pdf=|usr=}}
{{tp|p=34115904|t=2021. Asymmetrical cutaneous vasculitis following COVID-19 vaccination with unusual eosinophil preponderance.|pdf=|usr=}}
{{tp|p=34148333|t=2021. Updates on the coronavirus disease 2019 vaccine and consideration in children.|pdf=|usr=}}
{{tp|p=34111582|t=2021. Negative SARS-CoV-2 antibodies, T-cell response and virus neutralization following full vaccination in a renal transplant recipient: a call for vigilance.|pdf=|usr=}}
{{tp|p=34111577|t=2021. Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.|pdf=|usr=}}
{{tp|p=34174397|t=2021. B- and T-cell immune responses elicited by the Comirnaty(R) COVID-19 vaccine in nursing-home residents.|pdf=|usr=}}
{{tp|p=34129908|t=2021. Reconstituted mRNA COVID-19 vaccines may maintain stability after continuous movement.|pdf=|usr=}}
{{tp|p=34153456|t=2021. COVID-19 vaccination in solid-organ transplant recipients: generating new data as fast as possible, but taking clinical decisions as slow as necessary.|pdf=|usr=}}
{{tp|p=34115709|t=2021. COVID-19 Vaccination-Associated Lymphadenopathy on FDG PET/CT: Distinctive Features in Adenovirus-Vectored Vaccine.|pdf=|usr=}}
{{tp|p=34178877|t=2021. Ultrasound and shear-wave elastography patterns of COVID-19 mRNA vaccine-related axillary, supra and subclavicular lymphadenopathy.|pdf=|usr=}}
{{tp|p=34154428|t=2021. Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom.|pdf=|usr=}}
{{tp|p=34155052|t=2021. Feds sign off on mixing and matching COVID-19 vaccines, but evidence gaps remain.|pdf=|usr=}}
{{tp|p=34171857|t=2021. Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease.|pdf=|usr=}}
{{tp|p=34166950|t=2021. COVID-19 vaccination in patients with epilepsy: First experiences in a German tertiary epilepsy center.|pdf=|usr=}}
{{tp|p=34124587|t=2020. COVID-19 vaccine delivery: an opportunity to set up systems for the future.|pdf=|usr=}}
{{tp|p=34127050|t=2021. Landscape and selection of vaccine epitopes in SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34181021|t=2021. SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease-Fear and Desire.|pdf=|usr=}}
{{tp|p=34086060|t=2021. Acute reduction of visual acuity and visual field after Pfizer-BioNTech COVID-19 vaccine 2nd dose: a case report.|pdf=|usr=}}
{{tp|p=34179862|t=2021. A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primates.|pdf=|usr=}}
{{tp|p=34121813|t=2021. Challenges to COVID-19 vaccine supply chain: Implications for sustainable development goals.|pdf=|usr=}}
{{tp|p=34153381|t=2021. Radiation Recall Phenomenon Following COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34155853|t=2021. Immune Thrombocytopenic Purpura (ITP) Triggered by COVID-19 Infection and Vaccination.|pdf=|usr=}}
{{tp|p=34155844|t=2021. Immune Thrombocytopenia Following the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine.|pdf=|usr=}}
{{tp|p=34166844|t=2021. First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing.|pdf=|usr=}}
{{tp|p=34182162|t=2021. Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19.|pdf=|usr=}}
{{tp|p=34153517|t=2021. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach.|pdf=|usr=}}
{{tp|p=34112481|t=2021. Reply to "How important is the second dose of the COVID-19 mRNA vaccine?"|pdf=|usr=}}
{{tp|p=34112480|t=2021. How important is the second dose of the COVID-19 mRNA vaccine?|pdf=|usr=}}
{{tp|p=34162525|t=2021. "COVID Toes" After mRNA COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=34126274|t=2021. Allergic symptoms after mRNA COVID-19 vaccination and risk of incomplete vaccination.|pdf=|usr=}}
{{tp|p=34112378|t=2021. July 2021: Lisinopril for delayed inflammatory responses to hyaluronic acid fillers after COVID-19 vaccinations.|pdf=|usr=}}
{{tp|p=34148772|t=2021. Type 1 Kounis Syndrome Induced by Inactivated SARS-COV-2 Vaccine.|pdf=|usr=}}
{{tp|p=34131969|t=2021. Chilblain-like lesions after BNT162b2 mRNA COVID-19 vaccine: a case report suggesting that 'COVID toes' are due to the immune reaction to SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34131967|t=2021. Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine.|pdf=|usr=}}
{{tp|p=34112587|t=2021. Effectiveness of non-pharmaceutical interventions and vaccine for containing the spread of COVID-19: Three illustrations before and after vaccination periods.|pdf=|usr=}}
{{tp|p=34108119|t=2021. Economic evaluation for mass vaccination against COVID-19.|pdf=|usr=}}
{{tp|p=34175246|t=2021. Serological response to COVID-19 vaccination in patients with cancer older than 80 years.|pdf=|usr=}}
{{tp|p=34055326|t=2021. The largest vaccination campaign in history: A golden opportunity for bundling public health interventions.|pdf=|usr=}}
{{tp|p=34132638|t=2021. Immediate-Type Hypersensitivity to Polyethylene Glycol (PEG) Including a PEG-containing COVID-19 Vaccine Revealed by Intradermal Testing.|pdf=|usr=}}
{{tp|p=34121663|t=2021. Hypersensitivity to COVID-19 Vaccine Confirmed by a Positive Skin Test Result: A Case Report.|pdf=|usr=}}
{{tp|p=34128597|t=2021. Developing a Framework for Pandemic COVID-19 Vaccine Allocation: a Modified Delphi Consensus Study in Korea.|pdf=|usr=}}
{{tp|p=34184663|t=2021. SARS-CoV-2 Transmission Risk to Household and Family Contacts by Vaccinated Healthcare Workers.|pdf=|usr=}}
{{tp|p=34084042|t=2021. Need of Vibrant Vaccine Pharmacovigilance During Current Global COVID-19 Pandemic: More Than Ever.|pdf=|usr=}}
{{tp|p=34139754|t=2021. No COVID-19 vaccines on trash! Exploring effective vaccine management in the Philippines.|pdf=|usr=}}
{{tp|p=34129181|t=2021. Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis.|pdf=|usr=}}
{{tp|p=34128049|t=2021. High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data.|pdf=|usr=}}
{{tp|p=34132795|t=2021. Incidence of SARS-CoV-2 Infection in Health Care Workers After a Single Dose of mRNA-1273 Vaccine.|pdf=|usr=}}
{{tp|p=34140660|t=2021. Author Correction: A global database of COVID-19 vaccinations.|pdf=|usr=}}
{{tp|p=34158650|t=2021. Despite vaccination, China needs non-pharmaceutical interventions to prevent widespread outbreaks of COVID-19 in 2021.|pdf=|usr=}}
{{tp|p=34108714|t=2021. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.|pdf=|usr=}}
{{tp|p=34127854|t=2021. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals.|pdf=|usr=}}
{{tp|p=34108716|t=2021. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom.|pdf=|usr=}}
{{tp|p=34140665|t=2021. Using cross-species vaccination approaches to counter emerging infectious diseases.|pdf=|usr=}}
{{tp|p=34161961|t=2021. Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques.|pdf=|usr=}}
{{tp|p=34107529|t=2021. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.|pdf=|usr=}}
{{tp|p=34136730|t=2021. Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva.|pdf=|usr=}}
{{tp|p=34180130|t=2021. Varicella-Zoster virus reactivation following SARS-CoV-2 immunization in two patients with leukemia.|pdf=|usr=}}
{{tp|p=34173584|t=2020. Pfizer: The miracle vaccine for COVID-19?|pdf=|usr=}}
{{tp|p=34172292|t=2021. Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=34178176|t=2021. Mit der COVID-19-Impfung assoziierte rheumatische Beschwerden.|pdf=|usr=}}
{{tp|p=34159292|t=2021. COVID-19 vaccine failure in a patient on rituximab therapy.|pdf=|usr=}}
{{tp|p=34142203|t=2021. Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey.|pdf=|usr=}}
{{tp|p=34110465|t=2021. Safety and efficacy of COVID-19 vaccines in pregnant women with rheumatic diseases: an immunologic perspective.|pdf=|usr=}}
{{tp|p=34109466|t=2021. Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly.|pdf=|usr=}}
{{tp|p=34107667|t=2021. Utviklingshemmede og bruk av tvang ved vaksinering mot covid-19.|pdf=|usr=}}
{{tp|p=34107666|t=2021. Bor sykehjemsbeboere uten samtykkeevne vaksineres mot covid-19?|pdf=|usr=}}
{{tp|p=34182727|t=2021. Norge ma si ja til rettferdig tilgang til covid-19-vaksiner.|pdf=|usr=}}
{{tp|p=34088601|t=2021. Therapeutic plasma exchange (TPE) as a plausible rescue therapy in severe vaccine-induced immune thrombotic thrombocytopenia.|pdf=|usr=}}
{{tp|p=34131585|t=2021. Kidney Transplant Recipient Attitudes Toward a SARS-CoV-2 Vaccine.|pdf=|usr=}}
{{tp|p=34157078|t=2021. Strong SARS-CoV-2-neutralizing antibody response of previously-infected healthcare workers given one dose of mRNA vaccine.|pdf=|usr=}}
{{tp|p=34117878|t=2021. The SARS-CoV-2 mRNA vaccine breakthrough infection phenotype includes significant symptoms, live virus shedding, and viral genetic diversity.|pdf=|usr=}}
{{tp|p=34185632|t=2021. Is 'original antigenic sin' complicating indian vaccination drive against Covid-19?|pdf=|usr=}}
{{tp|p=34170791|t=2021. Recommendations for dermatologists treating patients with atopic dermatitis during the Covid-19 pandemic: a look into the past for a conscious vaccination management.|pdf=|usr=}}
{{tp|p=34170790|t=2021. Vaccine certificate during domestic traveling: a potential initiative to prevent COVID-19 waves in India.|pdf=|usr=}}
{{tp|p=34142925|t=2021. Attitudes of health care professionals towards COVID-19 vaccine - a sequence from Turkey.|pdf=|usr=}}
{{tp|p=34114939|t=2021. A rational strategy to support approved COVID-19 vaccines prioritization.|pdf=|usr=}}
{{tp|p=34135083|t=2021. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients.|pdf=|usr=}}
{{tp|p=34112706|t=2021. Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients.|pdf=|usr=}}
{{tp|p=34117129|t=2021. Antibody Response to COVID-19 Vaccination in Patients Receiving Dialysis.|pdf=|usr=}}
{{tp|p=34154501|t=2021. COVID-19 vaccination in pregnancy and postpartum.|pdf=|usr=}}
{{tp|p=34130586|t=2021. Coronavirus disease and vaccination during pregnancy and childbirth: a review of the Israeli perspective and experience.|pdf=|usr=}}
{{tp|p=34185044|t=2021. Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis: The Vaccine Safety Surveillance System Is Working.|pdf=|usr=}}
{{tp|p=34160555|t=2021. Incidence of Cutaneous Reactions After Messenger RNA COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=34110378|t=2021. Association of COVID-19 mRNA Vaccine With Ipsilateral Axillary Lymph Node Reactivity on Imaging.|pdf=|usr=}}
{{tp|p=34165512|t=2021. Association of COVID-19 Vaccination and Facial Nerve Palsy: A Case-Control Study.|pdf=|usr=}}
{{tp|p=34119059|t=2021. ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates - Authors' reply.|pdf=|usr=}}
{{tp|p=34119058|t=2021. ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates.|pdf=|usr=}}
{{tp|p=34111888|t=2021. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.|pdf=|usr=}}
{{tp|p=34113025|t=2020. Daily briefing: Coronavirus vaccine - where we are now.|pdf=|usr=}}
{{tp|p=34109409|t=2021. Weekly seroconversion rate of the mRNA-1273 SARS-CoV-2 vaccine in hemodialysis patients.|pdf=|usr=}}
{{tp|p=34120767|t=2021. One size does not fit all: Lessons from Israel's Covid-19 vaccination drive and hesitancy.|pdf=|usr=}}
{{tp|p=34112629|t=2021. Covid-19 - Le miracle vaccinal doit inclure rigueur et prudence.|pdf=|usr=}}
{{tp|p=34180608|t=2021. Biomaterials and nanomaterials for sustained release vaccine delivery.|pdf=|usr=}}

{{tp|p=34153512|t=2021. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases.|pdf=|usr=}}
{{tp|p=34133982|t=2021. Synthetic modified messenger RNA for therapeutic applications.|pdf=|usr=}}
{{tp|p=34169702|t=2021. Vaccines for COVID-19 in patients with atopic dermatitis: three things every dermatologist should know.|pdf=|usr=}}
{{tp|p=34181082|t=2021. Vaccination against COVID-19 infection: the need of evidence for diabetic and obese pregnant women.|pdf=|usr=}}
{{tp|p=34101024|t=2021. Cerebral venous sinus thrombosis 2 weeks after the first dose of mRNA SARS-CoV-2 vaccine.|pdf=|usr=}}
{{tp|p=34178577|t=2021. Immunologically relevant aspects of the new COVID-19 vaccines-an OGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper.|pdf=|usr=}}
{{tp|p=34153162|t=2021. Serological response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients depends on prior exposure to SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34144967|t=2021. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34127481|t=2021. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.|pdf=|usr=}}
{{tp|p=34131510|t=2021. COVID-19 vaccine-related lymph node activation - patterns of uptake on PET-CT.|pdf=|usr=}}
{{tp|p=34110406|t=2021. Vaccination against COVID-19: a challenge in CLL.|pdf=|usr=}}
{{tp|p=34110398|t=2021. Efficacy of COVID-19 vaccine in patients with CLL.|pdf=|usr=}}
{{tp|p=34137813|t=2021. A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34152403|t=2021. Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients.|pdf=|usr=}}
{{tp|p=34107889|t=2021. Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers.|pdf=|usr=}}
{{tp|p=34158352|t=2021. Blood clots, COVID-19 vaccines and the contraceptive pill: are we heading for a repeat of the 1995 pill scare?|pdf=|usr=}}
{{tp|p=34170008|t=2021. Response to correspondence in reference to the previously published Epub manuscript: immune thrombocytopenic purpura after SARS-CoV-2 vaccine.|pdf=|usr=}}
{{tp|p=34132395|t=2021. Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.|pdf=|usr=}}
{{tp|p=34159588|t=2021. Vaccine-induced immune thrombotic thrombocytopenia (VITT) - a novel clinico-pathological entity with heterogeneous clinical presentations.|pdf=|usr=}}
{{tp|p=34176130|t=2021. Cold agglutinin disease after COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34123321|t=2021. Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies.|pdf=|usr=}}
{{tp|p=34113842|t=2021. Transient akathisia after the SARS-Cov-2 vaccine.|pdf=|usr=}}
{{tp|p=34146727|t=2021. Liver injury after mRNA-based SARS-CoV-2 vaccination in a liver transplant recipient.|pdf=|usr=}}
{{tp|p=34113494|t=2021. Newly Diagnosed Idiopathic Thrombocytopenia Post COVID-19 Vaccine Administration.|pdf=|usr=}}
{{tp|p=34141500|t=2021. A Case of Cervical Lymphadenopathy After Vaccination Against COVID-19.|pdf=|usr=}}
{{tp|p=34150386|t=2021. A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination.|pdf=|usr=}}
{{tp|p=34150372|t=2021. Rhabdomyolysis Secondary to COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34165237|t=2021. Post Covid-19 vaccination papulovesicular pityriasis rosea-like eruption in a young male.|pdf=|usr=}}
{{tp|p=34185927|t=2021. Acute hyperglycaemic crisis after vaccination against COVID-19: A case series.|pdf=|usr=}}
{{tp|p=34186376|t=2021. Anti-PF4 antibody negative cerebral venous sinus thrombosis without thrombocytopenia following immunization with COVID-19 vaccine in an elderly non-comorbid Indian male, managed with conventional heparin-warfarin based anticoagulation.|pdf=|usr=}}
{{tp|p=34186348|t=2021. COVID-19 vaccine induced rhabdomyolysis: Case report with literature review.|pdf=|usr=}}
{{tp|p=34186339|t=2021. Exacerbation of hyperglycemia in patients with type 2 diabetes after vaccination for COVID19: Report of three cases.|pdf=|usr=}}
{{tp|p=34106430|t=2021. Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies?|pdf=|usr=}}
{{tp|p=34180795|t=2021. Intolerance Reaction After Vaccination Against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34109307|t=2021. Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine.|pdf=|usr=}}
{{tp|p=34099998|t=2021. Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment.|pdf=|usr=}}
{{tp|p=34102098|t=2021. Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February-March 2021.|pdf=|usr=}}
{{tp|p=34102097|t=2021. Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany.|pdf=|usr=}}
{{tp|p=34176436|t=2021. Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34120577|t=2021. Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination.|pdf=|usr=}}
{{tp|p=34110974|t=2021. Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution.|pdf=|usr=}}
{{tp|p=34123472|t=2021. Next Steps for Efficacy Evaluation in Clinical Trials of COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=34104127|t=2021. Advanced packaging for distribution and storage of COVID-19 vaccines: a review.|pdf=|usr=}}
{{tp|p=34117979|t=2021. Immune age and biological age as determinants of vaccine responsiveness among elderly populations: the Human Immunomics Initiative research program.|pdf=|usr=}}
{{tp|p=34158234|t=2021. Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine.|pdf=|usr=}}
{{tp|p=34164727|t=2021. Assessing immune response upon systemic RNA vaccination on [18F]-FDG PET/CT for COVID-19 vaccine and then for immuno-oncology?|pdf=|usr=}}
{{tp|p=34089336|t=2021. Management of mass casualties due to COVID-19: handling the dead.|pdf=|usr=}}
{{tp|p=34055838|t=2021. Challenges and Issues of Anti-SARS-CoV-2 Vaccines.|pdf=|usr=}}
{{tp|p=34144046|t=2021. Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease.|pdf=|usr=}}
{{tp|p=34144044|t=2021. COVID-19 Vaccination Is Safe and Effective in Patients With Inflammatory Bowel Disease: Analysis of a Large Multi-institutional Research Network in the United States.|pdf=|usr=}}
{{tp|p=34179698|t=2021. Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021.|pdf=|usr=}}
{{tp|p=34157386|t=2021. Countries with similar COVID-19 vaccination rates yet divergent outcomes: are all vaccines created equal?|pdf=|usr=}}
{{tp|p=34118427|t=2021. SARS-CoV-2 infection in properly vaccinated healthcare workers.|pdf=|usr=}}
{{tp|p=34116145|t=2021. Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19.|pdf=|usr=}}
{{tp|p=34129831|t=2021. Antibody Responses After mRNA-Based COVID-19 Vaccination in Residential Older Adults: Implications for Reopening.|pdf=|usr=}}
{{tp|p=34115991|t=2021. Emerging Evidence on Effectiveness of COVID-19 Vaccines Among Residents of Long-Term Care Facilities.|pdf=|usr=}}
{{tp|p=34170314|t=2021. SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses.|pdf=|usr=}}
{{tp|p=34129749|t=2021. Localized cutaneous reaction to an mRNA COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34169588|t=2021. Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2.|pdf=|usr=}}
{{tp|p=34169578|t=2021. The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?|pdf=|usr=}}
{{tp|p=34166540|t=2021. Delayed cutaneous reaction to ChAdOx1 nCoV-19 vaccine: Is it an 'AstraZeneca arm'?|pdf=|usr=}}
{{tp|p=34117873|t=2021. COVID-19 mRNA Vaccination Generates Greater Immunoglobulin G Levels in Women Compared to Men.|pdf=|usr=}}
{{tp|p=34166671|t=2021. Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent.|pdf=|usr=}}
{{tp|p=34165239|t=2021. Suggested treatment of serious complications to COVID-19 vaccination with IdeS, a bacterial antibody-cleaving enzyme.|pdf=|usr=}}
{{tp|p=34105247|t=2021. Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine.|pdf=|usr=}}
{{tp|p=34105244|t=2021. First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34117641|t=2021. The first known case of vaccine-induced thrombotic thrombocytopenia in Australia.|pdf=|usr=}}
{{tp|p=34142670|t=2021. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 among healthcare workers.|pdf=|usr=}}
{{tp|p=34142785|t=2021. Thrombosis following Covid-19 vaccination: a possible role of alcohol consumption? A suggestion from the Italian Society on Alcohol.|pdf=|usr=}}
{{tp|p=34132379|t=2021. COVID19 vaccination and IgG and IgA antibody dynamics in healthcare workers.|pdf=|usr=}}
{{tp|p=34161052|t=2021. SARS-CoV-2 Variants and Vaccines.|pdf=|usr=}}
{{tp|p=34077639|t=2021. Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study.|pdf=|usr=}}
{{tp|p=34161702|t=2021. Effect of Vaccination on Household Transmission of SARS-CoV-2 in England.|pdf=|usr=}}
{{tp|p=34107198|t=2021. Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia.|pdf=|usr=}}
{{tp|p=34161700|t=2021. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.|pdf=|usr=}}
{{tp|p=34126004|t=2021. Delayed Large Local Reactions to mRNA Covid-19 Vaccines in Blacks, Indigenous Persons, and People of Color.|pdf=|usr=}}
{{tp|p=34140469|t=2021. BNT162b2 vaccine uptake and effectiveness in UK healthcare workers - a single centre cohort study.|pdf=|usr=}}
{{tp|p=34117252|t=2021. SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung.|pdf=|usr=}}
{{tp|p=34131589|t=2021. Gamma irradiation-mediated inactivation of enveloped viruses with conservation of genome integrity: Potential application for SARS-CoV-2 inactivated vaccine development.|pdf=|usr=}}
{{tp|p=34152454|t=2021. Flimmernde Skotome nach COVID-Impfung : Eine weitere mogliche Impfnebenwirkung?|pdf=|usr=}}
{{tp|p=34172313|t=2021. Dosis unica de la vacuna SARS-CoV-2 m-ARN en personas mayores post-COVID-19.|pdf=|usr=}}
{{tp|p=34180617|t=2021. Vacuna frente al COVID-19.|pdf=|usr=}}
{{tp|p=34179695|t=2021. Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19.|pdf=|usr=}}
{{tp|p=34132229|t=2021. Low Immunization Rate in Kidney Transplant Recipients Also After Dose 2 of the BNT162b2 Vaccine: Continue to Keep Your Guard up!|pdf=|usr=}}
{{tp|p=34130883|t=2021. Interpreting vaccine efficacy trial results for infection and transmission.|pdf=|usr=}}
{{tp|p=34127291|t=2021. A new group at increased risk of a SARS-CoV-2 infection emerges: The recently vaccinated.|pdf=|usr=}}
{{tp|p=34120764|t=2021. Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models.|pdf=|usr=}}
{{tp|p=34119350|t=2021. Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization.|pdf=|usr=}}
{{tp|p=34167836|t=2021. The need for broadly protective COVID-19 vaccines: Beyond S-only approaches.|pdf=|usr=}}
{{tp|p=34147292|t=2021. Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects.|pdf=|usr=}}
{{tp|p=34151248|t=2021. Increasing efficiency in vaccine Production: A primer for change.|pdf=|usr=}}
{{tp|p=34069708|t=2021. ROS Cocktails as an Adjuvant for Personalized Antitumor Vaccination?|pdf=|usr=}}
{{tp|p=34167952|t=2021. Covid-19: Should we be worried about reports of myocarditis and pericarditis after mRNA vaccines?|pdf=|usr=}}
{{tp|p=34187101|t=2021. SARS-CoV-2 antibody assay after vaccination: one size does not fit all.|pdf=|usr=}}
{{tp|p=34162025|t=2021. Monitoring of the immunogenic response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers with Snibe SARS-CoV-2 S-RBD IgG chemiluminescent immunoassay.|pdf=|usr=}}
{{tp|p=34117084|t=2021. Vaccines and Disease Relapses in Children with Nephrotic Syndrome.|pdf=|usr=}}
{{tp|p=34183501|t=2021. 18F-Fluciclovine-Avid Reactive Axillary Lymph Nodes After COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34111682|t=2021. Successful treatment of acute spleno-porto-mesenteric vein thrombosis after ChAdOx1 nCoV-19 vaccine. A case report.|pdf=|usr=}}
{{tp|p=34176363|t=2021. The Levels of SARS-CoV-2 Specific Antibodies in Human Milk Following Vaccination.|pdf=|usr=}}
{{tp|p=34116590|t=2021. COVID-19 vaccine: the gender disparity.|pdf=|usr=}}
{{tp|p=34151698|t=2021. COVID-19 vaccination in patients on rituximab: a survey of lymphoma physicians at NCI designated cancer centers.|pdf=|usr=}}
{{tp|p=34134555|t=2021. Lupus, vaccinations and COVID-19: What we know now.|pdf=|usr=}}
{{tp|p=34101717|t=2021. In brief: Pfizer/BioNTech COVID-19 vaccine authorized for adolescents 12-15 years old.|pdf=|usr=}}
{{tp|p=34183852|t=2021. Building a pandemic-proof vaccine.|pdf=|usr=}}
{{tp|p=34108715|t=2021. COVID-19 vaccination and immune thrombocytopenia.|pdf=|usr=}}
{{tp|p=34113015|t=2021. Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals.|pdf=|usr=}}
{{tp|p=34145414|t=2021. Coronapod: CureVac disappoints in COVID vaccine trial.|pdf=|usr=}}
{{tp|p=34163051|t=2021. COVID vaccines and breastfeeding: what the data say.|pdf=|usr=}}
{{tp|p=34145413|t=2021. CureVac COVID vaccine let-down spotlights mRNA design challenges.|pdf=|usr=}}
{{tp|p=34158390|t=2021. COVID-19 vaccine side effects: The positives about feeling bad.|pdf=|usr=}}
{{tp|p=34131024|t=2021. SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques.|pdf=|usr=}}
{{tp|p=34131023|t=2021. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients.|pdf=|usr=}}

{{tp|p=34341771|t=2021. An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory.|pdf=|usr=}}
{{tp|p=34159636|t=2021. Vaccinating children and adolescents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-The Israeli experience.|pdf=|usr=}}
{{tp|p=34143448|t=2021. Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine.|pdf=|usr=}}
{{tp|p=34129694|t=2021. Delayed local reactions after the first administration of the ChAdOx1 nCoV-19 vaccine.|pdf=|usr=}}
{{tp|p=34128563|t=2021. COVID-19 vaccines and the role of other potential allergenic components different from PEG. A reply to: "Other excipients than PEG might cause serious hypersensitivity reactions in COVID-19 vaccines".|pdf=|usr=}}
{{tp|p=34101990|t=2021. Effectiveness of SARS-CoV-2 vaccination in fully vaccinated solid organ transplant recipients.|pdf=|usr=}}
{{tp|p=34125572|t=2021. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.|pdf=|usr=}}
{{tp|p=34125573|t=2021. Severe Exacerbations of Systemic Capillary Leak Syndrome After COVID-19 Vaccination: A Case Series.|pdf=|usr=}}
{{tp|p=34174097|t=2021. Estimating vaccine efficacy over time after a randomized study is unblinded.|pdf=|usr=}}
{{tp|p=34174765|t=2021. Potential immune response to breast implants after immunization with COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=34156582|t=2021. COVID-19 vaccination and breast cancer surgery timing.|pdf=|usr=}}
{{tp|p=34118375|t=2021. Myocarditis After SARS-CoV-2 Vaccination: A Vaccine-Induced Reaction?|pdf=|usr=}}
{{tp|p=34160784|t=2021. Using observational epidemiology to evaluate COVID-19 vaccines: integrating traditional methods with new data sources and tools.|pdf=|usr=}}
{{tp|p=34133941|t=2021. Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques.|pdf=|usr=}}
{{tp|p=34174992|t=2021. Antibody and B cell responses to SARS-CoV-2 infection and vaccination.|pdf=|usr=}}
{{tp|p=34133950|t=2021. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses.|pdf=|usr=}}
{{tp|p=34133885|t=2021. Myocarditis Temporally Associated With COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34133884|t=2021. Myocarditis After BNT162b2 and mRNA-1273 Vaccination.|pdf=|usr=}}
{{tp|p=34133883|t=2021. In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine.|pdf=|usr=}}
{{tp|p=34142570|t=2021. Expected Viscosity After COVID-19 Vaccination, Hyperviscosity and Previous COVID-19.|pdf=|usr=}}
{{tp|p=34166884|t=2021. Acute myocarditis after a second dose of the mRNA COVID-19 vaccine: a report of two cases.|pdf=|usr=}}
{{tp|p=34116295|t=2021. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up using ultrasonography.|pdf=|usr=}}
{{tp|p=34147649|t=2021. Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study.|pdf=|usr=}}
{{tp|p=34166499|t=2021. Poor Antibody Response after Two Doses of SARS-CoV-2 vaccine in Transplant Recipients.|pdf=|usr=}}
{{tp|p=34166484|t=2021. Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State.|pdf=|usr=}}
{{tp|p=34137815|t=2021. Post-vaccination SARS-CoV-2 infections and incidence of presumptive B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical center.|pdf=|usr=}}
{{tp|p=34134145|t=2021. The risk of symptomatic infection during a second COVID-19 wave, in SARS-CoV-2 seropositive individuals.|pdf=|usr=}}
{{tp|p=34134134|t=2021. Humoral and cellular immune responses against SARS-CoV-2 variants and human coronaviruses after single BNT162b2 vaccination.|pdf=|usr=}}
{{tp|p=34128970|t=2021. Antibodies to SARS-CoV-2 in All of Us Research Program Participants, January 2-March 18, 2020.|pdf=|usr=}}
{{tp|p=34156552|t=2021. [(18)F]FDG uptake of axillary lymph nodes after COVID-19 vaccination in oncological PET/CT: frequency, intensity, and potential clinical impact.|pdf=|usr=}}
{{tp|p=34140294|t=2021. Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype SARS-CoV-2 specific T cells.|pdf=|usr=}}
{{tp|p=34169819|t=2021. Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021.|pdf=|usr=}}
{{tp|p=34158652|t=2021. Acute macular neuroretinopathy following COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34077958|t=2021. Mandating Clinician COVID-19 Vaccination May Hinder Population-Level Uptake.|pdf=|usr=}}
{{tp|p=34184737|t=2021. Facial paralysis and vaccinations: a vaccine adverse event reporting system review.|pdf=|usr=}}
{{tp|p=34177237|t=2021. COVID-19 Vaccine in Veterans with Multiple Sclerosis: Protect the Vulnerable.|pdf=|usr=}}
{{tp|p=34148583|t=2021. Should women undergoing in vitro fertilization treatment or who are in the first trimester of pregnancy be vaccinated immediately against COVID-19.|pdf=|usr=}}
{{tp|p=34149815|t=2021. Correlation Between SARS-Cov-2 Vaccination, COVID-19 Incidence and Mortality: Tracking the Effect of Vaccination on Population Protection in Real Time.|pdf=|usr=}}
{{tp|p=34179072|t=2021. A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials.|pdf=|usr=}}
{{tp|p=34123704|t=2021. Outbreak of infections with the COVID-19 virus mutation B.1.351 about four weeks after the second successful vaccination with BNT162b2.|pdf=|usr=}}
{{tp|p=34123703|t=2021. Symptoms, antibody levels and vaccination attitude after asymptomatic to moderate COVID-19 infection in 200 healthcare workers.|pdf=|usr=}}
{{tp|p=34170788|t=2021. COVID-19 vaccine development from the perspective of cancer patients.|pdf=|usr=}}
{{tp|p=34161189|t=2021. Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies.|pdf=|usr=}}
{{tp|p=34114940|t=2021. The pivotal roles of the host immune response in the fine-tuning the infection and the development of the vaccines for SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34114927|t=2021. Are people previously infected with SARS-CoV-2 likely to experience COVID-19 symptoms again after vaccination? Results from an Italian COVID-19 referral center.|pdf=|usr=}}
{{tp|p=34145775|t=2021. Skin rashes after SARS-CoV-2 vaccine: which relationship, if any?|pdf=|usr=}}
{{tp|p=34145087|t=2021. Heterogeneity in protocols for bronchoalveolar lavage & sub-genomic RNA evaluation in non-human primate studies of SARS-CoV-2 vaccine candidates' evaluation.|pdf=|usr=}}
{{tp|p=34146066|t=2021. Corneal graft rejection after COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34167610|t=2021. Coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness in asymptomatic healthcare workers.|pdf=|usr=}}
{{tp|p=34176397|t=2021. Transmission of SARS-CoV-2 variant B.1.1.7 among vaccinated health care workers.|pdf=|usr=}}
{{tp|p=34174723|t=2021. Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data.|pdf=|usr=}}
{{tp|p=34139631|t=2021. Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines.|pdf=|usr=}}
{{tp|p=34177192|t=2021. COVID-19 vaccines in patients with chronic liver disease.|pdf=|usr=}}
{{tp|p=34143755|t=2021. Interpreting and addressing suboptimal immune responses after COVID-19 vaccination in solid-organ transplant recipients.|pdf=|usr=}}
{{tp|p=34144891|t=2021. COVID-19 vaccination immune paresis in heart and lung transplantation.|pdf=|usr=}}
{{tp|p=34120839|t=2021. Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients.|pdf=|usr=}}
{{tp|p=34116081|t=2021. Autoimmune hepatitis following SARS-CoV-2 vaccine: May not be a casuality.|pdf=|usr=}}
{{tp|p=34146650|t=2021. Reply to: "Comment on "Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?"".|pdf=|usr=}}
{{tp|p=34171435|t=2021. Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine.|pdf=|usr=}}
{{tp|p=34153398|t=2021. Autoimmune hepatitis following COVID-19 vaccination: True causality or mere association?|pdf=|usr=}}
{{tp|p=34129886|t=2021. Another case of autoimmune hepatitis after SARS-CoV-2 vaccination - still casualty?|pdf=|usr=}}
{{tp|p=34056008|t=2021. Induction of Humoral and Cellular Immunity by Intradermal Delivery of SARS-CoV-2 Nucleocapsid Protein Using Dissolvable Microneedles.|pdf=|usr=}}
{{tp|p=34117117|t=2021. Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients.|pdf=|usr=}}
{{tp|p=34161817|t=2021. Waning antibodies in SARS-CoV-2 naive vaccinees: Results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers.|pdf=|usr=}}
{{tp|p=34147528|t=2021. One year later: SARS-CoV-2 immune response and vaccination of healthcare workers post-infection.|pdf=|usr=}}
{{tp|p=34106888|t=2021. Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response.|pdf=|usr=}}
{{tp|p=34175235|t=2021. A patient presenting with ARDS after COVID-19 vaccination: A COVID-19 case report.|pdf=|usr=}}
{{tp|p=34119848|t=2021. Design of a novel multiple epitope-based vaccine: An immunoinformatics approach to combat SARS-CoV-2 strains.|pdf=|usr=}}
{{tp|p=34109263|t=2021. Localized and generalized urticarial allergic dermatitis secondary to SARS-CoV-2 vaccination in a series of 6 patients.|pdf=|usr=}}
{{tp|p=34174324|t=2021. Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective.|pdf=|usr=}}
{{tp|p=34137703|t=2021. Las variantes de SARS-CoV-2 y la llamada resistencia a las vacunas.|pdf=|usr=}}
{{tp|p=34137701|t=2021. Monitoreo activo de la seguridad temprana de la vacunacion con Sputnik V en Buenos Aires, Argentina.|pdf=|usr=}}
{{tp|p=34179744|t=2021. Vaccine induced thrombotic thrombocytopenia: The shady chapter of a success story.|pdf=|usr=}}
{{tp|p=34183681|t=2021. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.|pdf=|usr=}}
{{tp|p=34133415|t=2021. Human IgG and IgA responses to COVID-19 mRNA vaccines.|pdf=|usr=}}
{{tp|p=34149984|t=2021. Axillary lymphadenopathy in a renal cell carcinoma patient after COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34136745|t=2021. Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT).|pdf=|usr=}}
{{tp|p=34100388|t=2021. Use of COVID-19 vaccines in patients with liver disease and post-liver transplantation: Position statement of the Saudi association for the study of liver diseases and transplantation.|pdf=|usr=}}
{{tp|p=34286849|t=2021. Fine needle aspiration in COVID-19 vaccine-associated lymphadenopathy.|pdf=|usr=}}
{{tp|p=34173235|t=2021. The evolution of COVID-19 vaccination within a US blood center.|pdf=|usr=}}
{{tp|p=34172647|t=2021. Successful Liver Transplantation From a Deceased Donor With Vaccine-Induced Thrombotic Thrombocytopenia Causing Cerebral Venous Sinus and Hepatic Veins Thrombosis After ChAdOx1 nCov-19 Vaccination.|pdf=|usr=}}
{{tp|p=34155187|t=2021. Persistent Immunogenicity of the mRNA COVID-19 Vaccine in Patients Vaccinated Before Kidney Transplant.|pdf=|usr=}}
{{tp|p=34149002|t=2021. Immediate Impact of Induction Treatment on Postvaccination SARS-CoV-2 Serology in Kidney Transplant Recipients.|pdf=|usr=}}
{{tp|p=34238372|t=2021. Immunoinformatics approach for multi-epitope vaccine design against structural proteins and ORF1a polyprotein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).|pdf=|usr=}}
{{tp|p=34287384|t=2021. High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceara State, Brazil.|pdf=|usr=}}
{{tp|p=34090699|t=2021. Methodologic approaches in studies using real-world data (RWD) to measure pediatric safety and effectiveness of vaccines administered to pregnant women: A scoping review.|pdf=|usr=}}
{{tp|p=34204501|t=2021. Immune Response to Vaccination against COVID-19 in Breastfeeding Health Workers.|pdf=|usr=}}
{{tp|p=34204252|t=2021. First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers.|pdf=|usr=}}
{{tp|p=34203652|t=2021. Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart.|pdf=|usr=}}
{{tp|p=34198562|t=2021. Impacts of Side Effects to BNT162b2 and the First Dose of ChAdOx1 Anti-SARS-CoV-2 Vaccination on Work Productivity, the Need for Medical Attention, and Vaccine Acceptance: A Multicenter Survey on Healthcare Workers in Referral Teaching Hospitals in the Republic of Korea.|pdf=|usr=}}
{{tp|p=34208032|t=2021. A Murine CD8(+) T Cell Epitope Identified in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein.|pdf=|usr=}}
{{tp|p=34200648|t=2021. COVID-19 Vaccination in Patients with Classic Kaposi's Sarcoma.|pdf=|usr=}}
{{tp|p=34200587|t=2021. A Veterinary Vaccine for SARS-CoV-2: The First COVID-19 Vaccine for Animals.|pdf=|usr=}}
{{tp|p=34200538|t=2021. Interim Estimates of COVID-19 Vaccine Effectiveness in a Mass Vaccination Setting: Data from an Italian Province.|pdf=|usr=}}
{{tp|p=34206032|t=2021. Efficacy and Safety of COVID-19 Vaccines in Phase III Trials: A Meta-Analysis.|pdf=|usr=}}
{{tp|p=34304693|t=2021. COVID-19 variants as moving targets and how to stop them by glycoengineered whole-virus vaccines.|pdf=|usr=}}
{{tp|p=34087261|t=2021. Adenoviral Vector DNA- and SARS-CoV-2 mRNA-Based Covid-19 Vaccines: Possible Integration into the Human Genome - Are Adenoviral Genes Expressed in Vector-based Vaccines?|pdf=|usr=}}
{{tp|p=34277894|t=2021. A theoretical strategy for acceleration of human immune response against SARS-CoV-2: a fusion protein harboring virus-binding and pre-exposed antigen domains.|pdf=|usr=}}
{{tp|p=34206727|t=2021. Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil.|pdf=|usr=}}
{{tp|p=34205940|t=2021. DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination.|pdf=|usr=}}
{{tp|p=34181394|t=2021. Lipid Nanoparticles-From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement.|pdf=|usr=}}
{{tp|p=34159781|t=2021. Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses.|pdf=|usr=}}
{{tp|p=34147137|t=2021. Trombose, Hemorragia e Trombocitopenia Induzidas pelas Vacinas contra a COVID-19: Protocolo de Atuacao.|pdf=|usr=}}
{{tp|p=34112639|t=2021. Covid-19: AstraZeneca vaccine linked with small risk of ITP, real world data show.|pdf=|usr=}}
{{tp|p=34180390|t=2021. Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine.|pdf=|usr=}}
{{tp|p=34112673|t=2021. Mixing vaccines may boost immune responses.|pdf=|usr=}}
{{tp|p=34112671|t=2021. 'Landmark' African vaccine trial faces impasse.|pdf=|usr=}}
{{tp|p=34169493|t=2021. PF4-Dependent Immunoassays in Patients with Vaccine-Induced Immune Thrombotic Thrombocytopenia: Results of an Interlaboratory Comparison.|pdf=|usr=}}
{{tp|p=34096896|t=2021. Unique Imaging Findings of Neurologic Phantosmia Following Pfizer-BioNtech COVID-19 Vaccination: A Case Report.|pdf=|usr=}}
{{tp|p=34144554|t=2021. SARS-CoV-2 Vaccination, Immune Responses, and Antibody Testing in Immunosuppressed Populations: Tip of the Iceberg.|pdf=|usr=}}
{{tp|p=34115658|t=2021. Transplantation Outcome in Recipients Engrafted With Organs Recovered From the First French Deceased Donor With a SARS-COV-2 Vaccine-induced Thrombotic Thrombocytopenia.|pdf=|usr=}}
{{tp|p=34098566|t=2021. Antibody Response to the Janssen COVID-19 Vaccine in Solid Organ Transplant Recipients.|pdf=|usr=}}

{{tp|p=34309055|t=2021. Personalized health and the coronavirus vaccines-Do individual genetics matter?|pdf=|usr=}}
{{tp|p=34315454|t=2021. Evaluation of the safety profile of COVID-19 vaccines: a rapid review.|pdf=|usr=}}
{{tp|p=34304742|t=2021. Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals.|pdf=|usr=}}
{{tp|p=34256745|t=2021. Dynamic changes of functional fitness, antibodies to SARS-CoV-2 and immunological indicators within 1 year after discharge in Chinese health care workers with severe COVID-19: a cohort study.|pdf=|usr=}}
{{tp|p=34253200|t=2021. Optimal SARS-CoV-2 vaccine allocation using real-time attack-rate estimates in Rhode Island and Massachusetts.|pdf=|usr=}}
{{tp|p=34192529|t=2021. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2.|pdf=|usr=}}
{{tp|p=34242578|t=2021. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.|pdf=|usr=}}
{{tp|p=34265281|t=2021. Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses.|pdf=|usr=}}
{{tp|p=34265245|t=2021. The success of SARS-CoV-2 vaccines and challenges ahead.|pdf=|usr=}}
{{tp|p=34265240|t=2021. Beyond neutralization for BNT162b2 mRNA vaccination.|pdf=|usr=}}
{{tp|p=34282299|t=2021. Improvement of a SARS-CoV-2 vaccine by enhancing the conjugation efficiency of the immunogen to self-assembled nanoparticles.|pdf=|usr=}}
{{tp|p=34267334|t=2021. SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients.|pdf=|usr=}}
{{tp|p=34289385|t=2021. An intranasal vaccine durably protects against SARS-CoV-2 variants in mice.|pdf=|usr=}}
{{tp|p=34245672|t=2021. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters.|pdf=|usr=}}
{{tp|p=34293114|t=2021. The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living with HIV.|pdf=|usr=}}
{{tp|p=34282839|t=2021. Prevention of COVID-19 by mRNA-based vaccines within the general population of California.|pdf=|usr=}}
{{tp|p=34260716|t=2021. Evaluating Vaccine Efficacy Against SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=34278286|t=2021. Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals.|pdf=|usr=}}
{{tp|p=34278284|t=2021. A modelling study investigating short and medium-term challenges for COVID-19 vaccination: From prioritisation to the relaxation of measures.|pdf=|usr=}}
{{tp|p=34250456|t=2021. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial.|pdf=|usr=}}
{{tp|p=34222848|t=2021. Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study.|pdf=|usr=}}
{{tp|p=34296676|t=2021. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021.|pdf=|usr=}}
{{tp|p=34269175|t=2021. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021.|pdf=|usr=}}
{{tp|p=34269172|t=2021. Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England.|pdf=|usr=}}
{{tp|p=34240699|t=2021. An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021.|pdf=|usr=}}
{{tp|p=34212840|t=2021. Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021.|pdf=|usr=}}
{{tp|p=34212838|t=2021. Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel.|pdf=|usr=}}
{{tp|p=34322129|t=2021. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.|pdf=|usr=}}
{{tp|p=34276681|t=2021. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.|pdf=|usr=}}
{{tp|p=34262569|t=2021. Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=34249017|t=2021. Case Report: Sars-CoV-2 Infection in a Vaccinated Individual: Evaluation of the Immunological Profile and Virus Transmission Risk.|pdf=|usr=}}
{{tp|p=34248993|t=2021. Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets.|pdf=|usr=}}
{{tp|p=34234787|t=2021. Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis.|pdf=|usr=}}
{{tp|p=34220867|t=2021. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.|pdf=|usr=}}
{{tp|p=34220854|t=2021. Chronic Immune Activation and CD4(+) T Cell Lymphopenia in Healthy African Individuals: Perspectives for SARS-CoV-2 Vaccine Efficacy.|pdf=|usr=}}
{{tp|p=34211472|t=2021. Circulating Extracellular Vesicles Carry Immune Regulatory miRNAs and Regulate Vaccine Efficacy and Local Inflammatory Response After Vaccination.|pdf=|usr=}}
{{tp|p=34325615|t=2021. Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy.|pdf=|usr=}}
{{tp|p=34283001|t=2021. Early approval of COVID-19 vaccines: Pros and cons.|pdf=|usr=}}
{{tp|p=34254894|t=2021. Landscape and progress of global COVID-19 vaccine development.|pdf=|usr=}}
{{tp|p=34241575|t=2021. Can children of the Sputnik V vaccine recipients become symptomatic?|pdf=|usr=}}
{{tp|p=34242123|t=2021. SARS-CoV-2 vaccination in the context of original antigenic sin.|pdf=|usr=}}
{{tp|p=34324409|t=2021. Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers.|pdf=|usr=}}
{{tp|p=34189042|t=2021. Acute myocarditis following administration of BNT162b2 vaccine.|pdf=|usr=}}
{{tp|p=34314576|t=2021. SARS-CoV-2 spike glycoprotein-reactive T cells can be readily expanded from COVID-19 vaccinated donors.|pdf=|usr=}}
{{tp|p=34270939|t=2021. COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge.|pdf=|usr=}}
{{tp|p=34303920|t=2021. Antigenic sites in SARS-CoV-2 spike RBD show molecular similarity with pathogenic antigenic determinants and harbors peptides for vaccine development.|pdf=|usr=}}
{{tp|p=34324159|t=2021. Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab.|pdf=|usr=}}
{{tp|p=34242841|t=2021. Is the second dose of vaccination useful in previously SARS-CoV-2-infected healthcare workers?|pdf=|usr=}}
{{tp|p=34225791|t=2021. Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials.|pdf=|usr=}}
{{tp|p=34264514|t=2021. Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine.|pdf=|usr=}}
{{tp|p=34325045|t=2021. Letter to the Editor: Can the seasonal influenza vaccine for 2019/2020 have cross reactivity with some of the SARS-CoV-2 proteins?|pdf=|usr=}}
{{tp|p=34325043|t=2021. Influenza immunization and COVID-19-can viral structure be responsible for the effect?|pdf=|usr=}}
{{tp|p=34320413|t=2021. Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia.|pdf=|usr=}}
{{tp|p=34289406|t=2021. Anterior uveitis onset after bnt162b2 vaccination: is this just a coincidence?|pdf=|usr=}}
{{tp|p=34216738|t=2021. Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report.|pdf=|usr=}}
{{tp|p=34271203|t=2021. Reduction in COVID-19 prevalence in healthcare workers in a university hospital in southern Brazil after the start of vaccination.|pdf=|usr=}}
{{tp|p=34322400|t=2021. Diagnostic tools for evaluating the effectiveness of COVID 19 vaccines: Challenges and solution.|pdf=|usr=}}
{{tp|p=34294590|t=2021. Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report.|pdf=|usr=}}
{{tp|p=34247945|t=2021. Antibodies against Receptor Binding Domain of SARS-CoV-2 spike protein induced by BNT162b2 vaccine: results from a pragmatic, real-life study.|pdf=|usr=}}
{{tp|p=34303125|t=2021. Active Covid-19 infection and transmission after the first dose of the BNT162b2 mRNA vaccination in Saudi Arabia: A case report.|pdf=|usr=}}
{{tp|p=34293641|t=2021. SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naive and previously infected individuals.|pdf=|usr=}}
{{tp|p=34314037|t=2021. The dynamics of quantitative SARS-CoV-2 antispike IgG response to BNT162b2 vaccination.|pdf=|usr=}}
{{tp|p=34270094|t=2021. Safety of COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=34264528|t=2021. Safety and effectiveness of SARS-CoV-2 vaccines: A systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=34251683|t=2021. Relapse of microscopic polyangiitis after vaccination against COVID-19: A case report.|pdf=|usr=}}
{{tp|p=34197764|t=2021. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.|pdf=|usr=}}
{{tp|p=34324836|t=2021. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.|pdf=|usr=}}
{{tp|p=34308395|t=2021. Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19.|pdf=|usr=}}
{{tp|p=34223399|t=2021. Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK.|pdf=|usr=}}
{{tp|p=34258603|t=2021. Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study.|pdf=|usr=}}
{{tp|p=34318288|t=2021. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine.|pdf=|usr=}}
{{tp|p=34250518|t=2021. Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel.|pdf=|usr=}}
{{tp|p=34205564|t=2021. Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2.|pdf=|usr=}}
{{tp|p=34208751|t=2021. Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine.|pdf=|usr=}}
{{tp|p=34279108|t=2021. RBD-Modified Bacterial Vesicles Elicited Potential Protective Immunity against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34193869|t=2021. CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34326317|t=2021. Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers.|pdf=|usr=}}
{{tp|p=34258322|t=2021. Impact of Previous Coronavirus Disease 2019 on Immune Response After a Single Dose of BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.|pdf=|usr=}}
{{tp|p=34206507|t=2021. A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development.|pdf=|usr=}}
{{tp|p=34280210|t=2021. Modeling vaccination strategies in an Excel spreadsheet: Increasing the rate of vaccination is more effective than increasing the vaccination coverage for containing COVID-19.|pdf=|usr=}}
{{tp|p=34290317|t=2021. Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice.|pdf=|usr=}}
{{tp|p=34312010|t=2021. The Novel Platform of mRNA COVID-19 Vaccines and Myocarditis: Clues into the Potential Underlying Mechanism.|pdf=|usr=}}
{{tp|p=34304928|t=2021. An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity.|pdf=|usr=}}
{{tp|p=34303561|t=2021. Vitamin D supplementation: An alternative to enhance the effectiveness of vaccines against SARS-CoV-2?|pdf=|usr=}}
{{tp|p=34274126|t=2021. Significance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation.|pdf=|usr=}}
{{tp|p=34207916|t=2021. Vaccination in PADs.|pdf=|usr=}}
{{tp|p=34201330|t=2021. A Quantitative Benefit-Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy.|pdf=|usr=}}
{{tp|p=34201065|t=2021. Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination.|pdf=|usr=}}
{{tp|p=34208884|t=2021. Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines.|pdf=|usr=}}
{{tp|p=34206865|t=2021. Multi-Subunit SARS-CoV-2 Vaccine Design Using Evolutionarily Conserved T- and B- Cell Epitopes.|pdf=|usr=}}
{{tp|p=34202276|t=2021. Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination.|pdf=|usr=}}
{{tp|p=34206312|t=2021. Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI.|pdf=|usr=}}
{{tp|p=34199384|t=2021. Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans.|pdf=|usr=}}
{{tp|p=34199357|t=2021. Titers, Prevalence, and Duration of SARS-CoV-2 Antibodies in a Local COVID-19 Outbreak and Following Vaccination.|pdf=|usr=}}
{{tp|p=34207394|t=2021. Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia.|pdf=|usr=}}
{{tp|p=34207369|t=2021. Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States.|pdf=|usr=}}
{{tp|p=34207300|t=2021. BNT162b2 mRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers.|pdf=|usr=}}
{{tp|p=34205917|t=2021. Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=34205898|t=2021. Pancreatic Injury after COVID-19 Vaccine-A Case Report.|pdf=|usr=}}
{{tp|p=34205888|t=2021. The Beauty of Simplicity: Delayed-Type Hypersensitivity Reaction to Measure Cellular Immune Responses in RNA-SARS-Cov-2 Vaccinated Individuals.|pdf=|usr=}}
{{tp|p=34205861|t=2021. Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34207378|t=2021. Anti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants.|pdf=|usr=}}
{{tp|p=34417167|t=2021. Covid-19 booster vaccines: What we know and who's doing what.|pdf=|usr=}}
{{tp|p=34400478|t=2021. Intradermal covid-19 vaccination could solve supply problems.|pdf=|usr=}}
{{tp|p=34400411|t=2021. Covid-19: Two vaccine doses are crucial for protection against delta, study finds.|pdf=|usr=}}
{{tp|p=34251248|t=2021. Interrupting vaccination policies can greatly spread SARS-CoV-2 and enhance mortality from COVID-19 disease: The AstraZeneca case for France and Italy.|pdf=|usr=}}
{{tp|p=34236343|t=2021. Thrombosis with thrombocytopenia syndrome after COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34216472|t=2021. An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status.|pdf=|usr=}}
{{tp|p=34312162|t=2021. Humoral Response to mRNA versus an Adenovirus Vector-Based SARS-CoV-2 Vaccine in Dialysis Patients.|pdf=|usr=}}
{{tp|p=34281983|t=2021. COVID-19 Vaccination Imperatives in People on Maintenance Dialysis: An International Perspective.|pdf=|usr=}}
{{tp|p=34269723|t=2021. DOTATATE Uptake in an Axillary Lymph Node After COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34269722|t=2021. Features of Systemic Immune Response From COVID-19 Vaccination on 18F-FDG PET/CT.|pdf=|usr=}}

{{tp|p=34245636|t=2021. Reaching the hard to reach: Characteristics of patients who received a COVID-19 vaccine in the emergency department.|pdf=|usr=}}
{{tp|p=34310793|t=2021. Myopericarditis in young adults presenting to the emergency department after receiving a second COVID-19 mRNA vaccine.|pdf=|usr=}}
{{tp|p=34286517|t=2021. Cancer patients and internal medicine patients attitude towards COVID-19 vaccination in Poland.|pdf=|usr=}}
{{tp|p=34324884|t=2021. Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across.|pdf=|usr=}}
{{tp|p=34280513|t=2021. Prophylactic vaccine delivery systems against epidemic infectious diseases.|pdf=|usr=}}
{{tp|p=34277326|t=2021. Answers to burning questions for clinical allergologists related to the new COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=34370884|t=2021. Safe administration of the Pfizer-BioNtTech COVID-19 vaccine following an immediate reaction to the first dose.|pdf=|usr=}}
{{tp|p=34386995|t=2021. A single dose of BNT162b2 vaccine elicits strong humoral response in SARS-CoV-2 seropositive individuals.|pdf=|usr=}}
{{tp|p=34280507|t=2021. ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine.|pdf=|usr=}}
{{tp|p=34273435|t=2021. COVID-19 Vaccination in Immunoglobulin A Nephropathy.|pdf=|usr=}}
{{tp|p=34242687|t=2021. Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report.|pdf=|usr=}}
{{tp|p=34331842|t=2021. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients.|pdf=|usr=}}
{{tp|p=34331745|t=2021. COVID-19 after two doses of mRNA vaccines in kidney transplant recipients.|pdf=|usr=}}
{{tp|p=34370901|t=2021. Boosters and optimizing SARS-CoV-2 vaccine for transplantation: No time to wait.|pdf=|usr=}}
{{tp|p=34347934|t=2021. Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients.|pdf=|usr=}}
{{tp|p=34226070|t=2021. Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination.|pdf=|usr=}}
{{tp|p=34309715|t=2021. Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34302519|t=2021. Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis.|pdf=|usr=}}
{{tp|p=34274547|t=2021. Covid vaccination in patients with autoimmune diseases treated with mycophenolate: Let's think back to the recommendations.|pdf=|usr=}}
{{tp|p=34325334|t=2021. Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination.|pdf=|usr=}}
{{tp|p=34312487|t=2021. ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models.|pdf=|usr=}}
{{tp|p=34188432|t=2021. Modeling the impact of SARS-CoV-2 variants and vaccines on the spread of COVID-19.|pdf=|usr=}}
{{tp|p=34308402|t=2021. Case report of lymph node activation mimicking cancer progression: A false positive F(18) FDG PET CT after COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34202032|t=2021. Direct Measurement of B Lymphocyte Gene Expression Biomarkers in Peripheral Blood Transcriptomics Enables Early Prediction of Vaccine Seroconversion.|pdf=|usr=}}
{{tp|p=34192217|t=2020. SARS-CoV-2 Vaccine.|pdf=|usr=}}
{{tp|p=34320792|t=2021. It is time to adapt anti-CD20 administration schedule to allow efficient anti-SARS-Cov-2 vaccination in patients with lymphoid malignancies.|pdf=|usr=}}
{{tp|p=34320790|t=2021. Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies.|pdf=|usr=}}
{{tp|p=34320789|t=2021. Safety and efficacy of BNT162b mRNA Covid19 Vaccine in patients with chronic lymphocytic leukemia.|pdf=|usr=}}
{{tp|p=34195051|t=2021. A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report.|pdf=|usr=}}
{{tp|p=34288354|t=2021. Successful COVID-19 vaccination for patients on dialysis in Vilnius County.|pdf=|usr=}}
{{tp|p=34299876|t=2021. The Ecological Footprint of COVID-19 mRNA Vaccines: Estimating Greenhouse Gas Emissions in Germany.|pdf=|usr=}}
{{tp|p=34224924|t=2021. Safety of BNT162b2 mRNA COVID-19 vaccine in patients with mast cell disorders.|pdf=|usr=}}
{{tp|p=34293500|t=2021. Delayed cutaneous reactions after the administration of mRNA vaccines against COVID-19.|pdf=|usr=}}
{{tp|p=34293499|t=2021. An academic hospital experience screening mRNA COVID-19 vaccine risk using patient allergy history.|pdf=|usr=}}
{{tp|p=34246432|t=2021. Ascertainment Bias in Anaphylaxis Safety Data of COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=34293683|t=2021. Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: A novel clinical entity?|pdf=|usr=}}
{{tp|p=34237190|t=2021. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.|pdf=|usr=}}
{{tp|p=34237179|t=2021. Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients.|pdf=|usr=}}
{{tp|p=34309514|t=2021. Polyethylene glycol allergy and immediate-type hypersensivitity reaction to COVID-19 vaccination: case report.|pdf=|usr=}}
{{tp|p=34222851|t=2021. Major cardiac concerns in therapy and vaccinations for COVID-19.|pdf=|usr=}}
{{tp|p=34260903|t=2021. Partial protection of Sinopharm vaccine against SARS COV2 during recent outbreak in Bahrain.|pdf=|usr=}}
{{tp|p=34312390|t=2021. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants.|pdf=|usr=}}
{{tp|p=34312554|t=2021. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.|pdf=|usr=}}
{{tp|p=34262158|t=2021. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.|pdf=|usr=}}
{{tp|p=34290390|t=2021. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom.|pdf=|usr=}}
{{tp|p=34211186|t=2021. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans.|pdf=|usr=}}
{{tp|p=34320609|t=2021. Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine.|pdf=|usr=}}
{{tp|p=34326180|t=2021. COVID-19 and Vaccination in the Setting of Neurologic Disease: An Emerging Issue in Neurology.|pdf=|usr=}}
{{tp|p=34294728|t=2021. A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19.|pdf=|usr=}}
{{tp|p=34248208|t=2021. Is it possible to ensure COVID19 vaccine supply by using plants?|pdf=|usr=}}
{{tp|p=34267103|t=2021. Otologic Manifestations After COVID-19 Vaccination: The House Ear Clinic Experience.|pdf=|usr=}}
{{tp|p=34203729|t=2021. A Comprehensive Overview on the Production of Vaccines in Plant-Based Expression Systems and the Scope of Plant Biotechnology to Combat against SARS-CoV-2 Virus Pandemics.|pdf=|usr=}}
{{tp|p=34234013|t=2021. Design and proof of concept for targeted phage-based COVID-19 vaccination strategies with a streamlined cold-free supply chain.|pdf=|usr=}}
{{tp|p=34293165|t=2021. Herpes zoster following COVID-19 vaccine: a report of three cases.|pdf=|usr=}}
{{tp|p=34247246|t=2021. COVID-19 vaccine-associated acute cerebral venous thrombosis and pulmonary artery embolism.|pdf=|usr=}}
{{tp|p=34297134|t=2021. Letter re 'Breakthrough COVID-19 infections among health care workers after two doses of ChAdOx1 nCoV-19 vaccine'.|pdf=|usr=}}
{{tp|p=34297133|t=2021. The reversible tinnitus and cochleopathy followed first-dose AstraZeneca COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34297117|t=2021. Response to letter re Breakthrough COVID-19 infections among health care workers after two doses of ChAdOx1 nCoV-19 vaccine.|pdf=|usr=}}
{{tp|p=34297113|t=2021. COVID-19 vaccination effect on tracer uptake with FDG-PET/CT.|pdf=|usr=}}
{{tp|p=34192262|t=2020. Biovacc-19: A Candidate Vaccine for Covid-19 (SARS-CoV-2) Developed from Analysis of its General Method of Action for Infectivity.|pdf=|usr=}}
{{tp|p=34318475|t=2021. Vaccine for Covid-19 and Pregnant Women.|pdf=|usr=}}
{{tp|p=34306300|t=2021. Anaphylaxis and COVID-19 vaccines: Real-time interest using Google Trends.|pdf=|usr=}}
{{tp|p=34219448|t=2021. SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies.|pdf=|usr=}}
{{tp|p=34375049|t=2021. COVID-19 Vaccine-Associated Takotsubo Cardiomyopathy.|pdf=|usr=}}
{{tp|p=34453872|t=2021. Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients.|pdf=|usr=}}
{{tp|p=34431207|t=2021. Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept.|pdf=|usr=}}
{{tp|p=34326067|t=2021. Covid-19: NICE issues guidance on vaccine induced immune thrombocytopenia and thrombosis.|pdf=|usr=}}
{{tp|p=34301631|t=2021. Covid-19: Longer interval between Pfizer doses results in higher antibody levels, research finds.|pdf=|usr=}}
{{tp|p=34261628|t=2021. Covid-19: Regulators warn that rare Guillain-Barre cases may link to J&J and AstraZeneca vaccines.|pdf=|usr=}}
{{tp|p=34193597|t=2021. Cutting Edge: Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity.|pdf=|usr=}}
{{tp|p=34227230|t=2021. Anti-PF4 testing for vaccine-induced immune thrombocytopenia and thrombosis and heparin induced thrombocytopenia: Results from a UK National External Quality Assessment Scheme exercise April 2021.|pdf=|usr=}}
{{tp|p=34287612|t=2021. Bilateral Acute Macular Neuroretinopathy After Vaccination Against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34329200|t=2021. Septic Arthritis of the Shoulder After SARS-CoV-2 Pfizer Vaccination: A Case Report.|pdf=|usr=}}
{{tp|p=34308748|t=2021. Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies.|pdf=|usr=}}
{{tp|p=34313175|t=2021. Between a rock and a hard place: COVID-19 vaccination and patients on rituximab therapy.|pdf=|usr=}}
{{tp|p=34192958|t=2021. SARS-CoV-2 vaccination efficacy and B-cell depletion therapy in systemic lupus erythematosus: Description of a case.|pdf=|usr=}}
{{tp|p=34233102|t=2021. Audio Interview: How Well Are Covid-19 Vaccines Working?|pdf=|usr=}}
{{tp|p=34260844|t=2021. Audio Interview: Monoclonal Antibodies and Vaccine Boosts.|pdf=|usr=}}
{{tp|p=34192438|t=2021. Audio Interview: Another New Covid-19 Vaccine.|pdf=|usr=}}
{{tp|p=34192432|t=2021. Cerebral Venous Thrombosis.|pdf=|usr=}}
{{tp|p=34312555|t=2021. A 'mix and match' approach to SARS-CoV-2 vaccination.|pdf=|usr=}}
{{tp|p=34244681|t=2021. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.|pdf=|usr=}}
{{tp|p=34267382|t=2021. Another COVID-19 vaccine to boost rollout.|pdf=|usr=}}
{{tp|p=34239135|t=2021. A correlate of protection for SARS-CoV-2 vaccines is urgently needed.|pdf=|usr=}}
{{tp|p=34253930|t=2021. A French cohort for assessing COVID-19 vaccine responses in specific populations.|pdf=|usr=}}
{{tp|p=34226735|t=2021. Fractionation of COVID-19 vaccine doses could extend limited supplies and reduce mortality.|pdf=|usr=}}
{{tp|p=34244690|t=2021. Quarter-dose of Moderna COVID vaccine still rouses a big immune response.|pdf=|usr=}}
{{tp|p=34326510|t=2021. A blood marker predicts who gets 'breakthrough' COVID.|pdf=|usr=}}
{{tp|p=34215859|t=2021. Coronapod: the biomarker that could change COVID vaccines.|pdf=|usr=}}
{{tp|p=34272530|t=2021. Coronapod: does England's COVID strategy risk breeding deadly variants?|pdf=|usr=}}
{{tp|p=34211170|t=2021. Scientists identify long-sought marker for COVID vaccine success.|pdf=|usr=}}
{{tp|p=34230663|t=2021. Mounting evidence suggests Sputnik COVID vaccine is safe and effective.|pdf=|usr=}}
{{tp|p=34321643|t=2021. COVID vaccines slash viral spread - but Delta is an unknown.|pdf=|usr=}}
{{tp|p=34252919|t=2021. Systems vaccinology of the BNT162b2 mRNA vaccine in humans.|pdf=|usr=}}
{{tp|p=34233346|t=2021. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia.|pdf=|usr=}}
{{tp|p=34294926|t=2020. Daily briefing: The biotech building a better, faster, stronger coronavirus vaccine.|pdf=|usr=}}
{{tp|p=34285395|t=2020. Daily briefing: Three vaccines show early promise for COVID-19.|pdf=|usr=}}
{{tp|p=34228411|t=2021. Wat zijn de verschillen tussen diverse vaccins tegen COVID-19?|pdf=|usr=}}
{{tp|p=34312301|t=2021. Adenovirus-Vectored COVID-19 Vaccine-Induced Immune Thrombosis of Carotid Artery: A Case Report.|pdf=|usr=}}
{{tp|p=34275860|t=2021. Immunoinformatics approaches to explore B and T cell epitope-based vaccine designing for SARS-CoV-2 Virus.|pdf=|usr=}}
{{tp|p=34230101|t=2021. Reply to Dushoff et al. and Pifarre i Arolas et al.: Age prioritization for COVID-19 vaccination does save lives and years of life.|pdf=|usr=}}
{{tp|p=34230099|t=2021. Transmission dynamics are crucial to COVID-19 vaccination policy.|pdf=|usr=}}
{{tp|p=34328282|t=2021. The level of protective post-vaccination antibodies in NIPH-NIH employees after administration of Pfizer vaccine against COVID-19.|pdf=|usr=}}
{{tp|p=34264042|t=2021. Epidemiologie de COVID-19 et vaccination : etude de modelisation.|pdf=|usr=}}
{{tp|p=34215591|t=2021. Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34266981|t=2021. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.|pdf=|usr=}}
{{tp|p=34210786|t=2021. Implications of defective immune responses in SARS-CoV-2 vaccinated organ transplant recipients.|pdf=|usr=}}
{{tp|p=34315826|t=2021. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models.|pdf=|usr=}}
{{tp|p=34315825|t=2021. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates.|pdf=|usr=}}
{{tp|p=34285130|t=2021. A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters.|pdf=|usr=}}
{{tp|p=34244387|t=2021. Can immune responses predict which vaccines work best?|pdf=|usr=}}
{{tp|p=34326217|t=2021. The overlooked superpower of mRNA vaccines.|pdf=|usr=}}

{{tp|p=34455440|t=2021. COVID-19 vaccine use in immunocompromised patients: A commentary on evidence and recommendations.|pdf=|usr=}}
{{tp|p=34390501|t=2021. Serologic response to mRNA COVID-19 vaccination in lymphoma patients.|pdf=|usr=}}
{{tp|p=34331712|t=2021. Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib.|pdf=|usr=}}
{{tp|p=34363871|t=2021. Introduction of the BNT162b2 vaccine during a COVID-19 nursing home outbreak.|pdf=|usr=}}
{{tp|p=34352358|t=2021. Detection of neutralizing anti-severe acute respiratory syndrome coronavirus 2 antibodies in patients with common variable immunodeficiency after immunization with messenger RNA vaccines.|pdf=|usr=}}
{{tp|p=34343675|t=2021. Specific antibody response of patients with common variable immunodeficiency to BNT162b2 coronavirus disease 2019 vaccination.|pdf=|usr=}}
{{tp|p=34343674|t=2021. Biphasic anaphylaxis after first dose of messenger RNA coronavirus disease 2019 vaccine with positive polysorbate 80 skin testing result.|pdf=|usr=}}
{{tp|p=34333959|t=2021. Ipsilateral Axillary Adenopathy from mRNA COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=34305491|t=2021. Forecasting fully vaccinated people against COVID-19 and examining future vaccination rate for herd immunity in the US, Asia, Europe, Africa, South America, and the World.|pdf=|usr=}}
{{tp|p=34366169|t=2021. COVID-19 Vaccine Guidance for Patients with Cancer in Mexico: Report From the Working Group of the Mexican Society of Oncology.|pdf=|usr=}}
{{tp|p=34312136|t=2021. Acute encephalitis, myoclonus and Sweet syndrome after mRNA-1273 vaccine.|pdf=|usr=}}
{{tp|p=34281950|t=2021. Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses.|pdf=|usr=}}
{{tp|p=34261635|t=2021. Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34261633|t=2021. Coeliac artery and splenic artery thrombosis complicated with splenic infarction 7 days following the first dose of Oxford vaccination, causal relationship or coincidence?|pdf=|usr=}}
{{tp|p=34257129|t=2021. Thrombosis and thrombocytopaenia after ChAdOx1 nCoV-19 vaccination: a single UK centre experience.|pdf=|usr=}}
{{tp|p=34192020|t=2021. Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses.|pdf=|usr=}}
{{tp|p=34215611|t=2021. India's pragmatic vaccination strategy against COVID-19: a mathematical modelling-based analysis.|pdf=|usr=}}
{{tp|p=34220353|t=2021. Demonstrating the capacity of the National Advisory Committee on Immunization for timely responses to post-market vaccine monitoring signals: Canada's experience with the live-attenuated influenza vaccine.|pdf=|usr=}}
{{tp|p=34428917|t=2021. Myocarditis Associated With COVID-19 Vaccination: Echocardiography, Cardiac Tomography, and Magnetic Resonance Imaging Findings.|pdf=|usr=}}
{{tp|p=34283338|t=2021. Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine.|pdf=|usr=}}
{{tp|p=34324086|t=2021. The effect of a single dose of BNT162b2 vaccine on the incidence of severe COVID-19 infection in patients on chronic hemodialysis: a single-centre study.|pdf=|usr=}}
{{tp|p=34230841|t=2021. Emerging infectious diseases, vaccines and Guillain-Barre syndrome.|pdf=|usr=}}
{{tp|p=34222129|t=2021. Inside the story about the research and development of COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=34222128|t=2021. Fight against COVID-19 with mRNA vaccines and interaction with Dermal fillers.|pdf=|usr=}}
{{tp|p=34325221|t=2021. COVID-19 vaccine-related unilateral axillary lymphadenopathy: Pattern on screening breast MRI allowing for a benign assessment.|pdf=|usr=}}
{{tp|p=34303188|t=2021. Axillary adenopathy following COVID-19 vaccination: A single institution case series.|pdf=|usr=}}
{{tp|p=34298342|t=2021. Unilateral axillary adenopathy in the setting of COVID-19 vaccine: Follow-up.|pdf=|usr=}}
{{tp|p=34214649|t=2021. Detection of immunoglobulin response to COVID-19 vaccination using a novel rapid fingerstick assay.|pdf=|usr=}}
{{tp|p=34244723|t=2021. Single-dose mRNA vaccine effectiveness against SARS-CoV-2, including Alpha and Gamma variants: a test-negative design in adults 70 years and older in British Columbia, Canada.|pdf=|usr=}}
{{tp|p=34192576|t=2021. Improved immunogenicity against SARS-CoV-2 in a solid-organ transplant recipient by switching vaccines.|pdf=|usr=}}
{{tp|p=34265462|t=2021. Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data.|pdf=|usr=}}
{{tp|p=34245907|t=2021. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel.|pdf=|usr=}}
{{tp|p=34197936|t=2021. SARS-CoV-2 new infections among health-care workers after the first dose of the BNT162b2 mRNA COVID-19 vaccine. A hospital-wide cohort study.|pdf=|usr=}}
{{tp|p=34329793|t=2021. Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study.|pdf=|usr=}}
{{tp|p=34277256|t=2021. New-Onset Neurologic Symptoms and Related Neuro-Oncologic Lesions Discovered After COVID-19 Vaccination: Two Neurosurgical Cases and Review of Post-Vaccine Inflammatory Responses.|pdf=|usr=}}
{{tp|p=34277203|t=2021. A Case of COVID-19 Vaccine Causing a Myasthenia Gravis Crisis.|pdf=|usr=}}
{{tp|p=34277198|t=2021. Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=34268022|t=2021. COVID-19 Vaccination-Induced Rash: Does the Choice of Vaccine Matter?|pdf=|usr=}}
{{tp|p=34235030|t=2021. Subacute Thyroiditis After Receiving the Adenovirus-Vectored Vaccine for Coronavirus Disease (COVID-19).|pdf=|usr=}}
{{tp|p=34293552|t=2021. COVID-19 vaccine-induced myocarditis: Case report with literature review.|pdf=|usr=}}
{{tp|p=34284226|t=2021. Elucidating causes of COVID-19 infection and related deaths after vaccination.|pdf=|usr=}}
{{tp|p=34280733|t=2021. Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study.|pdf=|usr=}}
{{tp|p=34206567|t=2021. Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine.|pdf=|usr=}}
{{tp|p=34288285|t=2021. Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel.|pdf=|usr=}}
{{tp|p=34189948|t=2021. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34258873|t=2021. A case of severe autoimmune hemolytic anemia after a receipt of a first dose of SARS-CoV-2 vaccine.|pdf=|usr=}}
{{tp|p=34251972|t=2021. Adverse rare events to vaccines for COVID-19: From hypersensitivity reactions to thrombosis and thrombocytopenia.|pdf=|usr=}}
{{tp|p=34275656|t=2021. Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34271109|t=2021. Placebo-controlled trials with COVID-19 vaccines: participants first.|pdf=|usr=}}
{{tp|p=34271108|t=2021. Ethics of COVID-19 vaccine trials in rapidly changing contexts.|pdf=|usr=}}
{{tp|p=34305352|t=2021. Exercise caution with ChAdOx1 COVID-19 vaccination in Chronic Budd-Chiari syndrome with a thrombophilic genetic predisposition.|pdf=|usr=}}
{{tp|p=34291391|t=2021. Safety of COVID-19 Vaccination in Immune-Deficient Patients Receiving Supplemental Immunoglobulin Therapies.|pdf=|usr=}}
{{tp|p=34202817|t=2021. Neurosurgical Considerations Regarding Decompressive Craniectomy for Intracerebral Hemorrhage after SARS-CoV-2-Vaccination in Vaccine Induced Thrombotic Thrombocytopenia-VITT.|pdf=|usr=}}
{{tp|p=34203769|t=2021. Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey.|pdf=|usr=}}
{{tp|p=34323111|t=2021. Analysis of Continuous Blood Glucose Data in People with Type 1 Diabetes (T1DM) After COVID-19 Vaccination Indicates a Possible Link Between the Immune and the Metabolic Response.|pdf=|usr=}}
{{tp|p=34281760|t=2021. Acute corneal endothelial graft rejection following COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34291376|t=2021. Delayed Hypersensitivity Reactions Following First Dose of the SARS-CoV2 mRNA Vaccines.|pdf=|usr=}}
{{tp|p=34232526|t=2021. SARS-CoV-2 vaccine-induced prothrombotic immune thrombocytopenia: Promoting awareness to improve patient-doctor trust.|pdf=|usr=}}
{{tp|p=34214206|t=2021. AstraZeneca (AZD1222) COVID-19 vaccine-associated adverse drug event: A case report.|pdf=|usr=}}
{{tp|p=34284342|t=2021. Hyperacute reversible encephalopathy related to cytokine storm following COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34274719|t=2021. Commentary: The spectrum of neurological manifestations related to COVID-19 and vaccinations.|pdf=|usr=}}
{{tp|p=34224024|t=2021. Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination.|pdf=|usr=}}
{{tp|p=34228985|t=2021. Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents.|pdf=|usr=}}
{{tp|p=34219532|t=2021. Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database.|pdf=|usr=}}
{{tp|p=34210829|t=2021. A Case of Chilblains-like Lesions Post SARS-CoV-2 Vaccine?|pdf=|usr=}}
{{tp|p=34314875|t=2021. Secondary thrombocytopenia after SARS-CoV-2 vaccine: Report of a case of hemorrhage and hematoma after minor oral surgery.|pdf=|usr=}}
{{tp|p=34312992|t=2021. Laboratory testing for post ChAdOx1 nCOV-19 vaccination VITT: A challenge. Comment on: Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology.|pdf=|usr=}}
{{tp|p=34224753|t=2021. Serological response to a single dose of a SARS-CoV-2 mRNA vaccine.|pdf=|usr=}}
{{tp|p=34246586|t=2021. Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings.|pdf=|usr=}}
{{tp|p=34246585|t=2021. A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2.|pdf=|usr=}}
{{tp|p=34236995|t=2021. Physiologic Response to the Pfizer-BioNTech COVID-19 Vaccine Measured Using Wearable Devices: Prospective Observational Study.|pdf=|usr=}}
{{tp|p=34218852|t=2021. Vaccination Safety: Don't Toss the Champagne With the Cork.|pdf=|usr=}}
{{tp|p=34222853|t=2021. A colloidal gold-based immunochromatographic strip for rapid detection of SARS-CoV-2 antibodies after vaccination.|pdf=|usr=}}
{{tp|p=34235592|t=2021. Vaccination of cancer patients against COVID-19: towards the end of a dilemma.|pdf=|usr=}}
{{tp|p=34198208|t=2021. Maternal vaccines during the Covid-19 pandemic:A qualitative interview study with UK pregnant women.|pdf=|usr=}}
{{tp|p=34189662|t=2021. Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19.|pdf=|usr=}}
{{tp|p=34324120|t=2021. Functional neurological disorder after COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34322761|t=2021. Bell's palsy following COVID-19 vaccination with high CSF antibody response.|pdf=|usr=}}
{{tp|p=34272622|t=2021. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine.|pdf=|usr=}}
{{tp|p=34260633|t=2021. The impact of vaccination to control COVID-19 burden in the United States: A simulation modeling approach.|pdf=|usr=}}
{{tp|p=34245485|t=2021. Delirium in a patient with Alzheimer's dementia following COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34306275|t=2021. Quadrilateral space region inflammation and other incidental findings on shoulder MRI following recent COVID-19 vaccination: Three case reports.|pdf=|usr=}}
{{tp|p=34327553|t=2021. Hirnvenen- und Sinusthrombose nach COVID-19-Schutzimpfung : Neurologisch-radiologisches Prozedere.|pdf=|usr=}}
{{tp|p=34244818|t=2021. Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt.|pdf=|usr=}}
{{tp|p=34325717|t=2021. Modelling the impact of delaying vaccination against SARS-CoV-2 assuming unlimited vaccine supply.|pdf=|usr=}}
{{tp|p=34324256|t=2021. Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients.|pdf=|usr=}}
{{tp|p=34288294|t=2021. Transplantation programs facing lack of empirical evidence on SARS-CoV-2 vaccination: A society recommendation consensus update.|pdf=|usr=}}
{{tp|p=34214738|t=2021. Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study.|pdf=|usr=}}
{{tp|p=34293520|t=2021. Serologic Responses following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients.|pdf=|usr=}}
{{tp|p=34274492|t=2021. Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients.|pdf=|usr=}}
{{tp|p=34319928|t=2021. Breakthrough COVID-19 Infections After mRNA Vaccination in Solid Organ Transplant Recipients in Miami, Florida.|pdf=|usr=}}
{{tp|p=34241987|t=2021. Antibody Kinetics and Durability in SARS-CoV-2 mRNA Vaccinated Solid Organ Transplant Recipients.|pdf=|usr=}}
{{tp|p=34310531|t=2021. Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients.|pdf=|usr=}}
{{tp|p=34310530|t=2021. Two Doses of SARS-CoV-2 Vaccines Reduce Risk of Death Due to COVID-19 in Solid Organ Transplant Recipients: Preliminary Outcomes From a UK Registry Linkage Analysis.|pdf=|usr=}}
{{tp|p=34310101|t=2021. Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies.|pdf=|usr=}}
{{tp|p=34284420|t=2021. SARS-CoV-2 Messenger RNA Vaccine Immunogenicity in Solid Organ Transplant Recipients With Prior COVID-19.|pdf=|usr=}}
{{tp|p=34198360|t=2021. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34235275|t=2021. Vaccine-enhanced disease: case studies and ethical implications for research and public health.|pdf=|usr=}}
{{tp|p=34370541|t=2021. Support Pharmacy Infrastructure to Strengthen US COVID-19 Vaccination Efforts and Beyond.|pdf=|usr=}}
{{tp|p=34370533|t=2021. Vaccination of the Elderly in Assisted Living by the Israeli Emergency Medical Services.|pdf=|usr=}}
{{tp|p=34355820|t=2021. Successful vertical transmission of SARS-CoV-2 antibodies after maternal vaccination.|pdf=|usr=}}
{{tp|p=34330713|t=2021. Covid-19: Pfizer vaccine's efficacy declined from 96% to 84% four months after second dose, company reports.|pdf=|usr=}}
{{tp|p=34373255|t=2021. Covid-19: How effective are vaccines against the delta variant?|pdf=|usr=}}
{{tp|p=34429324|t=2021. Covid-19: 40% of patients with weakened immune system mount lower response to vaccines.|pdf=|usr=}}
{{tp|p=34259661|t=2021. Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia.|pdf=|usr=}}
{{tp|p=34227078|t=2021. Side effects after COVID-19 vaccinations among residents of Poland.|pdf=|usr=}}
{{tp|p=34197272|t=2021. Safety of Sars-Cov-2 vaccines administration for adult patients with hereditary fructose intolerance.|pdf=|usr=}}
{{tp|p=34196589|t=2021. Subacute thyroiditis following COVID-19 vaccination in a 67-year-old male patient: a case report.|pdf=|usr=}}
{{tp|p=34303332|t=2021. Genetics and Vaccine development for SARS-CoV2 in the era of Personalized Medicine.|pdf=|usr=}}
{{tp|p=34271824|t=2021. Thrombotic Thrombocytopenia and Central Venous Sinus Thrombosis Post - COVID-19 Vaccination and its Treatment with Heparin Alternatives.|pdf=|usr=}}
{{tp|p=34301834|t=2021. Mix and match COVID-19 vaccines: potential benefit and perspective from India.|pdf=|usr=}}
{{tp|p=34224542|t=2021. SARS-CoV-2 Vaccination and Antibody Testing in Immunosuppressed Populations: You Can't Tell the Players Without a Scorecard [RETRACTED].|pdf=|usr=}}

{{tp|p=34364905|t=2021. Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine in a Multicenter Cohort of Nursing Home Residents Receiving Maintenance Hemodialysis.|pdf=|usr=}}
{{tp|p=34352250|t=2021. Presence of SARS-CoV-2 antibodies in lactating women and their infants following BNT162b2 messenger RNA vaccine.|pdf=|usr=}}
{{tp|p=34358478|t=2021. Adjustment is required to calculate the risk of early pregnancy loss with COVID-19 infection or vaccination.|pdf=|usr=}}
{{tp|p=34461029|t=2021. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study.|pdf=|usr=}}
{{tp|p=34429320|t=2021. Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases.|pdf=|usr=}}
{{tp|p=34308389|t=2021. Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose.|pdf=|usr=}}
{{tp|p=34267349|t=2021. Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34237213|t=2021. Thrombosis and severe acute respiratory syndrome coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia.|pdf=|usr=}}
{{tp|p=34222134|t=2021. A rare case of shingles after COVID-19 vaccine: is it a possible adverse effect?|pdf=|usr=}}
{{tp|p=34222133|t=2021. Acute myocarditis associated with anti-COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34280870|t=2021. Coronavirus disease 2019 vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up: A monocentre study.|pdf=|usr=}}
{{tp|p=34243079|t=2021. Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer.|pdf=|usr=}}
{{tp|p=34233234|t=2021. The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience.|pdf=|usr=}}
{{tp|p=34217909|t=2021. High levels of anti-SARS-CoV-2 IgG antibodies in previously infected patients with cancer after a single dose of BNT 162b2 vaccine.|pdf=|usr=}}
{{tp|p=34309530|t=2021. Considerations on SARS-Cov-2 vaccines in patients with autoimmune blistering diseases.|pdf=|usr=}}
{{tp|p=34263984|t=2021. Efficacy of the COVID-19 vaccine in heart transplant recipients: what we know and what we ignore.|pdf=|usr=}}
{{tp|p=34315774|t=2021. Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021.|pdf=|usr=}}
{{tp|p=34256983|t=2021. Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT).|pdf=|usr=}}
{{tp|p=34244023|t=2021. Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against COVID-19 pandemic: What pathogenesis?|pdf=|usr=}}
{{tp|p=34293217|t=2021. Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency.|pdf=|usr=}}
{{tp|p=34264151|t=2021. Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=34313516|t=2021. Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34288409|t=2021. COVID-19 vaccines: what do we know so far?|pdf=|usr=}}
{{tp|p=34213434|t=2021. COVID-19 vaccine effectiveness in preventing deaths among high-risk sgroups in Tamil Nadu, India.|pdf=|usr=}}
{{tp|p=34216120|t=2021. Which Group Should be Vaccinated First?: A Systematic Review.|pdf=|usr=}}
{{tp|p=34218826|t=2021. The use of antibody tests to determine level of immunity against coronavirus disease 2019 (COVID-19) after vaccination: A recent trend in India.|pdf=|usr=}}
{{tp|p=34289927|t=2021. SARS-CoV-2 vaccine breakthrough infections among healthcare workers in a large Belgian hospital network.|pdf=|usr=}}
{{tp|p=34261574|t=2021. Adverse events and humoral response after two doses of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) mRNA vaccine in the hospital personnel of a cardiopulmonary tertiary-care center.|pdf=|usr=}}
{{tp|p=34276178|t=2021. Delayed Skin Rash After Receiving SARS-CoV-2 mRNA Moderna Vaccine.|pdf=|usr=}}
{{tp|p=34276177|t=2021. Acute Necrotizing Rhombencephalitis and Disemminated Thrombosis After SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=34276176|t=2021. CDC Recommends Concurrent Immunizations: Does the COVID-19 Vaccination Campaign Offer Opportunities for Improving Vaccination Rates Across the Lifespan?|pdf=|usr=}}
{{tp|p=34286453|t=2021. Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular application of the vaccine?|pdf=|usr=}}
{{tp|p=34280851|t=2021. Autoimmune phenomena following SARS-CoV-2 vaccination.|pdf=|usr=}}
{{tp|p=34244309|t=2021. Do people reduce compliance with COVID-19 guidelines following vaccination? A longitudinal analysis of matched UK adults.|pdf=|usr=}}
{{tp|p=34310777|t=2021. New-onset acral lesions on hands after administration of mRNA-1273 vaccine against SARS-CoV-2: clinical images and histopathological study of three cases.|pdf=|usr=}}
{{tp|p=34310766|t=2021. Omalizumab prevents anaphylactoid reactions to mRNA COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34310763|t=2021. Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34310759|t=2021. Small vessel vasculitis related to varicella-zoster virus after Pfizer-BioNTech COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34310755|t=2021. A skin reaction with rust-like discolouration to mRNA COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34310754|t=2021. Herpes Zoster following SARS-CoV-2 vaccination - a series of four cases.|pdf=|usr=}}
{{tp|p=34309932|t=2021. New onset of mainly guttate psoriasis after COVID-19 vaccination: a case report.|pdf=|usr=}}
{{tp|p=34243220|t=2021. Transition of cutaneous into systemic lupus erythematosus following adenoviral vector-based SARS-CoV-2 vaccination.|pdf=|usr=}}
{{tp|p=34242422|t=2021. 'COVID arm' - histological features of a delayed-type hypersensitivity reaction to Moderna mRNA-1273 SARS-CoV2 vaccine.|pdf=|usr=}}
{{tp|p=34237178|t=2021. Pityriasis rosea developing after COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34236736|t=2021. Development of eruptive pseudoangiomatosis following COVID-19 immunization - Apropos of 5 cases.|pdf=|usr=}}
{{tp|p=34236735|t=2021. Pernio-like skin lesions after the second dose of Pfizer-BioNTech COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34236729|t=2021. Generalized eczematous reactions to the Pfizer-BioNTech COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34236728|t=2021. New onset of remitting seronegative symmetrical synovitis with pitting oedema and palmoplantar psoriasis flare-up after Sars-Cov-2 vaccination.|pdf=|usr=}}
{{tp|p=34236718|t=2021. New-onset cutaneous lichen planus triggered by COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34236717|t=2021. Widespread purpura annularis telangiectodes following mRNA SARS-CoV-2 vaccine.|pdf=|usr=}}
{{tp|p=34310778|t=2021. Pityriasis rubra pilaris after Vaxzevria(R) COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34309085|t=2021. Retiform purpura and extensive skin necrosis as the single manifestation of SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=34324939|t=2021. Cross reactivity of serological response to SARS-CoV-2 vaccination with viral variants of concern detected by lateral flow immunoassays.|pdf=|usr=}}
{{tp|p=34214517|t=2021. Limited protection against SARS-CoV-2 infection and virus transmission after mRNA vaccination.|pdf=|usr=}}
{{tp|p=34233149|t=2021. Importance of sample dilution in the evaluation of the antibody response after SARS-CoV-2 vaccination.|pdf=|usr=}}
{{tp|p=34214516|t=2021. Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers.|pdf=|usr=}}
{{tp|p=34279930|t=2021. Potent Neutralizing Antibodies Elicited by RBD-Fc-Based COVID-19 Vaccine Candidate Adjuvanted by the Th2-Skewing iNKT Cell Agonist.|pdf=|usr=}}
{{tp|p=34316507|t=2021. Varicella zoster virus reactivation and mRNA vaccines as a trigger.|pdf=|usr=}}
{{tp|p=34316506|t=2021. Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination.|pdf=|usr=}}
{{tp|p=34222572|t=2021. Cutaneous mucormycosis following COVID-19 vaccination in a patient with bullous pemphigoid.|pdf=|usr=}}
{{tp|p=34192257|t=2021. Educational Resource Review: Vaccine development: finding a vaccine for COVID-19 and future pandemics.|pdf=|usr=}}
{{tp|p=34270945|t=2021. Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.|pdf=|usr=}}
{{tp|p=34237324|t=2021. IgA nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34237323|t=2021. Granulomatous vasculitis after the AstraZeneca anti-SARS-CoV-2 vaccine.|pdf=|usr=}}
{{tp|p=34216675|t=2021. Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis.|pdf=|usr=}}
{{tp|p=34284044|t=2021. The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis.|pdf=|usr=}}
{{tp|p=34316525|t=2021. Neutralizing SARS-CoV-2 Antibody Response and Protective Effect of 2 Doses of ChAdOx1 nCoV-19 and BBV152 Vaccines in Hemodialysis Patients: A Preliminary Report.|pdf=|usr=}}
{{tp|p=34250319|t=2021. Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD.|pdf=|usr=}}
{{tp|p=34250318|t=2021. Nephrotic Syndrome Following ChAdOx1 nCoV-19 Vaccine Against SARScoV-2.|pdf=|usr=}}
{{tp|p=34278290|t=2021. IgA Nephropathy After SARS-CoV-2 Vaccination.|pdf=|usr=}}
{{tp|p=34274038|t=2021. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1.|pdf=|usr=}}
{{tp|p=34270933|t=2021. Antibody response after second BNT162b2 dose in allogeneic HSCT recipients.|pdf=|usr=}}
{{tp|p=34246358|t=2021. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.|pdf=|usr=}}
{{tp|p=34274035|t=2021. Protecting the vulnerable: SARS-CoV-2 vaccination in immunosuppressed patients with interstitial lung disease.|pdf=|usr=}}
{{tp|p=34224675|t=2021. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.|pdf=|usr=}}
{{tp|p=34307057|t=2021. SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic study.|pdf=|usr=}}
{{tp|p=34216636|t=2021. Optimal allocation of limited vaccine to minimize the effective reproduction number.|pdf=|usr=}}
{{tp|p=34230920|t=2021. Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=34223401|t=2021. FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system.|pdf=|usr=}}
{{tp|p=34229883|t=2021. Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine.|pdf=|usr=}}
{{tp|p=34229882|t=2021. Lesiones similares a perniosis tras vacunacion con ARNm frente a COVID-19.|pdf=|usr=}}
{{tp|p=34298479|t=2021. Key points to keep in mind related to COVID-19 vaccines in people with multiple sclerosis.|pdf=|usr=}}
{{tp|p=34298478|t=2021. Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies.|pdf=|usr=}}
{{tp|p=34260850|t=2021. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination.|pdf=|usr=}}
{{tp|p=34233109|t=2021. Breakthrough SARS-CoV-2 Infections in Prison after Vaccination.|pdf=|usr=}}
{{tp|p=34192426|t=2021. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.|pdf=|usr=}}
{{tp|p=34233097|t=2021. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile.|pdf=|usr=}}
{{tp|p=34320281|t=2021. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.|pdf=|usr=}}
{{tp|p=34192428|t=2021. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.|pdf=|usr=}}
{{tp|p=34233107|t=2021. Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia.|pdf=|usr=}}
{{tp|p=34232359|t=2021. Die Corona-Pandemie und Multiple Sklerose: Impfungen und deren Implikationen fur Patienten - Teil 1: Empfehlungen.|pdf=|usr=}}
{{tp|p=34232358|t=2021. Die Corona-Pandemie und Multiple Sklerose: Impfungen und deren Implikationen fur Patienten - Teil 2: Impfstofftechnologien.|pdf=|usr=}}
{{tp|p=34271959|t=2021. Gene therapies and COVID-19 vaccines: a necessary discussion in relation with viral vector-based approaches.|pdf=|usr=}}
{{tp|p=34270597|t=2021. Beyond the new normal: Assessing the feasibility of vaccine-based suppression of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34324966|t=2021. Developmental and reproductive safety of AZD1222 (ChAdOx1 nCoV-19) in mice.|pdf=|usr=}}
{{tp|p=34210623|t=2021. Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan.|pdf=|usr=}}
{{tp|p=34247902|t=2021. Henoch-Schonlein purpura presenting post COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34226102|t=2021. Laser-facilitated epicutaneous immunization of mice with SARS-CoV-2 spike protein induces antibodies inhibiting spike/ACE2 binding.|pdf=|usr=}}
{{tp|p=34217573|t=2021. Specialist confirmed allergic reactions to COVID-19 mRNA vaccines at a mass vaccination site.|pdf=|usr=}}
{{tp|p=34215453|t=2021. Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration.|pdf=|usr=}}
{{tp|p=34210574|t=2021. Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease: A case control study.|pdf=|usr=}}
{{tp|p=34210573|t=2021. Evidence for antibody as a protective correlate for COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=34272095|t=2021. Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia.|pdf=|usr=}}
{{tp|p=34253420|t=2021. One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model.|pdf=|usr=}}
{{tp|p=34253419|t=2021. Initial impact of SARS-Cov-2 vaccination on healthcare workers in Italy- Update on the 28th of March 2021.|pdf=|usr=}}
{{tp|p=34275671|t=2021. Inadequate deltoid muscle penetration and concerns of improper COVID mRNA vaccine administration can be avoided by injection technique modification.|pdf=|usr=}}
{{tp|p=34340982|t=2021. Response to: Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli et al.|pdf=|usr=}}
{{tp|p=34340981|t=2021. Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli et al.|pdf=|usr=}}
{{tp|p=34340979|t=2021. Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response"by Bonelli et al.|pdf=|usr=}}
{{tp|p=34340978|t=2021. Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli et al.|pdf=|usr=}}
{{tp|p=34417362|t=2021. COVID-19 Vaccination Associated with Reduced Post-Operative SARS-CoV-2 Infection and Morbidity.|pdf=|usr=}}
{{tp|p=34227891|t=2021. Postinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2.|pdf=|usr=}}

{{tp|p=34406720|t=2021. COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT)|pdf=|usr=}}
{{tp|p=34257025|t=2021. COVID-19 Vaccination Induced Lymphadenopathy in a Specialized Breast Imaging Clinic in Israel: Analysis of 163 cases.|pdf=|usr=}}
{{tp|p=34273260|t=2021. Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis.|pdf=|usr=}}
{{tp|p=34396603|t=2021. Large-Sized Graphene Oxide Nanosheets Increase DC-T-Cell Synaptic Contact and the Efficacy of DC Vaccines against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34377976|t=2021. Commentary on: A Case Report of Capsular Contracture Immediately Following COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34373851|t=2021. A Case Report of Capsular Contracture Immediately Following COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34394211|t=2020. Invited Editorial. COVID-19 Vaccine: Hope and reality.|pdf=|usr=}}
{{tp|p=34342475|t=2021. Perspectives on COVID-19 vaccination for pregnant women in South Africa.|pdf=|usr=}}
{{tp|p=34212542|t=2021. COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group.|pdf=|usr=}}
{{tp|p=34249404|t=2021. Two Cases of Well Controlled Chronic Spontaneous Urticaria Triggered by the Moderna COVID-19 Vaccine.|pdf=|usr=}}
{{tp|p=34304240|t=2021. BNT162b2 mRNA Vaccine Interference with Co-Administration of Tdap Vaccine.|pdf=|usr=}}
{{tp|p=34285180|t=2021. A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34254431|t=2021. Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19.|pdf=|usr=}}
{{tp|p=34241963|t=2021. Positive flow cytometry crossmatch with discrepant antibody testing results following COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34241964|t=2021. Antibodies, boosters, and optimizing SARS-CoV-2 vaccines for transplantation: A call for more research.|pdf=|usr=}}
{{tp|p=34328268|t=2021. Response to "SARS-CoV-2 vaccine effectiveness trumps immunogenicity in solid organ transplant recipients".|pdf=|usr=}}
{{tp|p=34212494|t=2021. SARS-CoV-2 vaccine effectiveness trumps immunogenicity in solid organ transplant recipients.|pdf=|usr=}}
{{tp|p=34249353|t=2021. Post-COVID-19 vaccine Guillain-Barre syndrome; first reported case from Qatar.|pdf=|usr=}}
{{tp|p=34336204|t=2021. Shoulder injury related to Sinovac COVID-19 vaccine: A case report.|pdf=|usr=}}
{{tp|p=34306673|t=2021. SARS-CoV-2 vaccinations are unsafe for those experiencing post-vaccination Guillain-Barre syndrome.|pdf=|usr=}}
{{tp|p=34324214|t=2021. Postvaccinal Encephalitis after ChAdOx1 nCov-19.|pdf=|usr=}}
{{tp|p=34333128|t=2021. Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients.|pdf=|usr=}}
{{tp|p=34362747|t=2021. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.|pdf=|usr=}}
{{tp|p=34286215|t=2021. Safety and immunogenicity evaluation of inactivated whole-virus-SARS-COV-2 as emerging vaccine development in Egypt.|pdf=|usr=}}
{{tp|p=34246566|t=2021. COVID-19 vaccines and myocarditis.|pdf=|usr=}}
{{tp|p=34280598|t=2021. COVID-19 vaccination and frailty in older adults.|pdf=|usr=}}
{{tp|p=34189565|t=2021. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.|pdf=|usr=}}
{{tp|p=34297792|t=2021. Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19).|pdf=|usr=}}
{{tp|p=34280256|t=2021. Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein.|pdf=|usr=}}
{{tp|p=34323939|t=2021. Prothrombotic immune thrombocytopenia after COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34255033|t=2021. Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination.|pdf=|usr=}}
{{tp|p=34187803|t=2021. Case of Guillain-Barre syndrome following COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34254291|t=2021. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.|pdf=|usr=}}
{{tp|p=34196388|t=2021. Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma.|pdf=|usr=}}
{{tp|p=34192245|t=2021. Aphasia seven days after second dose of an mRNA-based SARS-CoV-2 vaccine.|pdf=|usr=}}
{{tp|p=34310400|t=2021. Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial.|pdf=|usr=}}
{{tp|p=34231698|t=2021. Contexto de elaboracao do Plano de Imunizacao contra COVID-19 no Brasil.|pdf=|usr=}}
{{tp|p=34275963|t=2021. Frequent Premature Ventricular Contraction and Non-Sustained Ventricular Tachycardia After the SARS-CoV-2 Vaccination in Patient With Implantable Cardioverter Defibrillator Due to Acquired Long-QT Syndrome.|pdf=|usr=}}
{{tp|p=34235757|t=2021. Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal haemorrhage.|pdf=|usr=}}
{{tp|p=34272751|t=2021. Can COVID-19 immunisation cause subacute thyroiditis?|pdf=|usr=}}
{{tp|p=34318537|t=2021. IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to mRNA COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=34189756|t=2021. Cutaneous thrombosis associated with skin necrosis following Oxford-AstraZeneca COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34236714|t=2021. Vitiligo in a COVID-19-vaccinated patient with ulcerative colitis: coincidence?|pdf=|usr=}}
{{tp|p=34236711|t=2021. Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature.|pdf=|usr=}}
{{tp|p=34291477|t=2021. Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA-based or adenoviral vector-based SARS-CoV-2 vaccination.|pdf=|usr=}}
{{tp|p=34288056|t=2021. Delayed localized hypersensitivity reactions to COVID-19 mRNA vaccines: a 6-month retrospective study.|pdf=|usr=}}
{{tp|p=34260095|t=2021. Severe cutaneous adverse reaction following COVID-19 vaccination and immunotherapy: a second hit?|pdf=|usr=}}
{{tp|p=34275716|t=2021. COVID-19 Vaccination in Oncology Patients Receiving Chemotherapy.|pdf=|usr=}}
{{tp|p=34243221|t=2021. US Taxpayers Heavily Funded the Discovery of COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=34241676|t=2021. Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.|pdf=|usr=}}
{{tp|p=34241675|t=2021. SARS-CoV-2 vaccination in cardiothoracic organ transplant recipients: effective strategies wanted.|pdf=|usr=}}
{{tp|p=34241923|t=2021. Ethical considerations regarding COVID-19 vaccination for transplant candidates and recipients.|pdf=|usr=}}
{{tp|p=34327795|t=2021. Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine.|pdf=|usr=}}
{{tp|p=34245963|t=2021. Trend in COVID-19 vaccination among people with diabetes: A short study from India.|pdf=|usr=}}
{{tp|p=34275974|t=2021. Emergency use of COVID-19 vaccines recommended by the World Health Organization (WHO) as of June 2021.|pdf=|usr=}}
{{tp|p=34234059|t=2021. Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19.|pdf=|usr=}}
{{tp|p=34243217|t=2021. Subjektives Wohlbefinden und Arbeitsfahigkeit von Krankenhauspersonal nach SARS-CoV-2-Immunisierung mit dem mRNS-Impfstoff BNT162b2 - Ergebnisse einer anonymen Umfrage.|pdf=|usr=}}
{{tp|p=34233498|t=2021. Otolaryngology-Specific Symptoms May Be Highly Observed in Patients With a History of Covid-19 Infection After Inactivated Coronavirus Vaccination.|pdf=|usr=}}
{{tp|p=34308319|t=2021. Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India.|pdf=|usr=}}
{{tp|p=34308302|t=2021. Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality.|pdf=|usr=}}
{{tp|p=34226899|t=2021. Acquired thrombotic thrombocytopenic purpura with possible association with AstraZeneca-Oxford COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34226903|t=2021. Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients.|pdf=|usr=}}
{{tp|p=34314670|t=2021. Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities, Spain.|pdf=|usr=}}
{{tp|p=34289335|t=2021. Breakthrough Infections of SARS-CoV-2 Gamma Variant in Fully Vaccinated Gold Miners, French Guiana, 2021.|pdf=|usr=}}
{{tp|p=34304724|t=2021. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.|pdf=|usr=}}
{{tp|p=34289779|t=2021. Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19.|pdf=|usr=}}
{{tp|p=34278956|t=2021. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.|pdf=|usr=}}
{{tp|p=34232116|t=2021. Antibody titres decline 3-month post-vaccination with BNT162b2.|pdf=|usr=}}
{{tp|p=34197281|t=2021. Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial.|pdf=|usr=}}
{{tp|p=34268278|t=2021. Renal Vein Thrombosis and Pulmonary Embolism Secondary to Vaccine-induced Thrombotic Thrombocytopenia (VITT).|pdf=|usr=}}
{{tp|p=34268277|t=2021. COVID-19 mRNA Vaccine and Myocarditis.|pdf=|usr=}}
{{tp|p=34268264|t=2021. The Meaning of SARS-CoV-2 Antibodies in a Patient with a Systemic Reaction to the mRNA-1273 SARS-CoV-2 Vaccine after Previous Natural Immunization.|pdf=|usr=}}
{{tp|p=34250222|t=2021. Current vaccine technology with an emphasis on recombinant measles virus as a new perspective for vaccination against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34266487|t=2021. COVID-19 vaccination associated severe immune thrombocytopenia.|pdf=|usr=}}
{{tp|p=34290613|t=2021. Targeting SARS-CoV-2-Platelet Interactions in COVID-19 and Vaccine-Related Thrombosis.|pdf=|usr=}}
{{tp|p=34290884|t=2021. An observational study of a cohort of citizens receiving the AZD1222 vaccine against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34249141|t=2021. Safety, efficacy and acceptability of SARS-CoV-2 vaccines in patients with cancer.|pdf=|usr=}}
{{tp|p=34270523|t=2021. Vacunas contra la COVID-19 y aparicion de variantes del SARS-CoV-2. Reflexionando sobre el caso de Mexico.|pdf=|usr=}}
{{tp|p=34224740|t=2021. BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign.|pdf=|usr=}}
{{tp|p=34267426|t=2021. NOTTO COVID-19 Vaccine Guidelines for Transplant Recipients.|pdf=|usr=}}
{{tp|p=34315833|t=2021. Breastfeeding and Coronavirus Disease 2019 (COVID-19) Vaccination: Position Statement of Indian Academy of Pediatrics Advisory Committee on Vaccination and Immunization Practices.|pdf=|usr=}}
{{tp|p=34251026|t=2021. COVID-19 vaccination: possible short-term exacerbations of oral mucosal diseases.|pdf=|usr=}}
{{tp|p=34241833|t=2021. New-onset leukocytoclastic vasculitis after COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34244126|t=2021. COVID-19 vaccination among Spanish nephrologists: Acceptance and side effects.|pdf=|usr=}}
{{tp|p=34274181|t=2021. Paucisymptomatic COVID-19 in lung transplant recipient following two doses of mRNA-1273 (Moderna) vaccine.|pdf=|usr=}}
{{tp|p=34325728|t=2021. Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia.|pdf=|usr=}}
{{tp|p=34256064|t=2021. An unusual case of acute cholestatic hepatitis after m-RNABNT162b2 (Comirnaty) SARS-CoV-2 vaccine: Coincidence, autoimmunity or drug-related liver injury.|pdf=|usr=}}
{{tp|p=34245804|t=2021. The mRNA COVID-19 vaccine - A rare trigger of autoimmune hepatitis?|pdf=|usr=}}
{{tp|p=34189719|t=2021. Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.|pdf=|usr=}}
{{tp|p=34304294|t=2021. Misinterpretation of glioblastoma as ADEM: potentially harmful consequences of over-diagnosis of COVID-19 vaccine-associated adverse events.|pdf=|usr=}}
{{tp|p=34253304|t=2021. COVID-19 Vaccination in Pregnancy: The Benefits Outweigh the Risks.|pdf=|usr=}}
{{tp|p=34273222|t=2021. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine: COMMENT from Gruel et al.: RESPONSE from Kahn et al.|pdf=|usr=}}
{{tp|p=34226895|t=2021. A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus.|pdf=|usr=}}
{{tp|p=34212511|t=2021. COVID-19 vaccines are effective in people with obesity: A position statement from The Obesity Society.|pdf=|usr=}}
{{tp|p=34307734|t=2021. Acute Immune Thrombocytopenia (ITP) Following COVID-19 Vaccination in a Patient With Previously Stable ITP.|pdf=|usr=}}
{{tp|p=34264546|t=2021. SARS-CoV-2 vaccination for adolescents and young adult patients treated at a specialist pediatric oncology unit.|pdf=|usr=}}
{{tp|p=34291552|t=2021. Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients.|pdf=|usr=}}
{{tp|p=34187780|t=2021. Covid-19: Third vaccine dose boosts immune response but may not be needed, say researchers.|pdf=|usr=}}
{{tp|p=34219142|t=2021. Tracking the pipeline: immunoinformatics and the COVID-19 vaccine design.|pdf=|usr=}}
{{tp|p=34213848|t=2021. SARS-CoV-2 vaccines, where do we stand?|pdf=|usr=}}
{{tp|p=34272229|t=2021. Patients with Solid Tumors Seroconvert after SARS-CoV-2 mRNA Vaccine.|pdf=|usr=}}
{{tp|p=34233902|t=2021. COVID-19 Vaccines Complicate Mammograms.|pdf=|usr=}}
{{tp|p=34269740|t=2021. Immunization practices and risk of anaphylaxis: a current update, comprehensive of COVID-19 vaccination data.|pdf=|usr=}}
{{tp|p=34314309|t=2021. COVID-19 Vaccine Reactions in Dermatology: "Filling" in the Gaps.|pdf=|usr=}}
{{tp|p=34231348|t=2021. Management of patients at risk of anaphylaxis after COVID 19 vaccination.|pdf=|usr=}}
{{tp|p=34261746|t=2021. Bilateral facial weakness with paraesthesia variant of Guillain-Barre syndrome following Vaxzevria COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34261345|t=Fall. Functional Neurological Disorder After SARS-CoV-2 Vaccines: Two Case Reports and Discussion of Potential Public Health Implications.|pdf=|usr=}}
{{tp|p=34301777|t=2021. Lessons learned from post-COVID-19 vaccination PET/CT studies.|pdf=|usr=}}
{{tp|p=34264684|t=2021. Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines.|pdf=|usr=}}
{{tp|p=34187278|t=2021. Acute Macular Neuroretinopathy following Coronavirus Disease 2019 Vaccination.|pdf=|usr=}}
{{tp|p=34282035|t=2021. Enhancement of Cell-based Vaccine Manufacturing Through Process Intensification.|pdf=|usr=}}
{{tp|p=34217513|t=2021. Guillain-Barre syndrome following first injection of ChAdOx1 nCoV-19 vaccine: First report.|pdf=|usr=}}

{{tp|p=34257485|t=2021. Addressing Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following COVID-19 Vaccination: A Mini-Review of Practical Strategies.|pdf=|usr=}}
{{tp|p=34436620|t=2021. Exacerbation of Hailey-Hailey Disease Following SARS-CoV-2 Vaccination.|pdf=|usr=}}
{{tp|p=34273119|t=2021. Large hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: A case report.|pdf=|usr=}}
{{tp|p=34366434|t=2021. Ulceras De Lipschutz Tras La Vacuna Frente A La Covid-19 De Astrazeneca.|pdf=|usr=}}
{{tp|p=34396358|t=2021. Myocarditis following mRNA vaccination against SARS-CoV-2, a case series.|pdf=|usr=}}
{{tp|p=34399967|t=2021. COVID-19 Vaccine and Myocarditis.|pdf=|usr=}}
{{tp|p=34364657|t=2021. Acute Myocardial Infarction Within 24 Hours After COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34229940|t=2021. Myocarditis after BNT162b2 vaccination in a healthy male.|pdf=|usr=}}
{{tp|p=34274191|t=2021. A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination.|pdf=|usr=}}
{{tp|p=34389291|t=2021. COVID-19 vaccination during pregnancy: coverage and safety.|pdf=|usr=}}
{{tp|p=34425297|t=2021. Pregnancy and birth outcomes after SARS-CoV-2 vaccination in pregnancy.|pdf=|usr=}}
{{tp|p=34411758|t=2021. COVID-19 vaccination in pregnancy: early experience from a single institution.|pdf=|usr=}}
{{tp|p=34236331|t=2021. Acute myocarditis after the second dose of SARS-CoV-2 vaccine: Serendipity or atypical causal relationship?|pdf=|usr=}}
{{tp|p=34288044|t=2021. COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany.|pdf=|usr=}}
{{tp|p=34231246|t=2021. Functional Neurological Disorders and COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34342013|t=2021. Development, evaluation and use of COVID-19 vaccines in older adults: Preliminary principles for the pandemic and beyond.|pdf=|usr=}}
{{tp|p=34346068|t=2021. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.|pdf=|usr=}}
{{tp|p=34341984|t=2021. COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myeloma.|pdf=|usr=}}
{{tp|p=34405400|t=2021. Thrombotic thrombocytopenic purpura temporally associated with BNT162b2 vaccination in an adolescent successfully treated with caplacizumab.|pdf=|usr=}}
{{tp|p=34331459|t=2021. Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine.|pdf=|usr=}}
{{tp|p=34242573|t=2021. Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution.|pdf=|usr=}}
{{tp|p=34242572|t=2021. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma.|pdf=|usr=}}
{{tp|p=34242571|t=2021. Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient.|pdf=|usr=}}
{{tp|p=34214473|t=2021. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer.|pdf=|usr=}}
{{tp|p=34298785|t=2021. COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience.|pdf=|usr=}}
{{tp|p=34320400|t=2021. Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding.|pdf=|usr=}}
{{tp|p=34250287|t=2021. Effects of COVID-19 vaccination on FDG-PET/CT imaging: A literature review.|pdf=|usr=}}
{{tp|p=34278231|t=2021. Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis.|pdf=|usr=}}
{{tp|p=34263143|t=2021. Autoimmune Hematologic Disorders in Two Patients After mRNA COVID-19 Vaccine.|pdf=|usr=}}
{{tp|p=34221846|t=2021. Prediction and identification of T cell epitopes of COVID-19 with balanced cytokine response for the development of peptide based vaccines.|pdf=|usr=}}
{{tp|p=34279767|t=2021. COVID-19 vaccines and decreased transmission of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34241782|t=2021. Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies.|pdf=|usr=}}
{{tp|p=34322977|t=2021. Perspectives of dermatology specialists and residents on COVID-19 vaccines: A questionnaire-based survey.|pdf=|usr=}}
{{tp|p=34228863|t=2021. Adverse reactions to Pfizer-BioNTech vaccination of healthcare workers at Malta's state hospital.|pdf=|usr=}}
{{tp|p=34289643|t=2021. The potential interaction between COVID-19 vaccines and clozapine: A novel approach for clinical trials.|pdf=|usr=}}
{{tp|p=34276266|t=2021. Lessons Learned from Cutting-Edge Immunoinformatics on Next-Generation COVID-19 Vaccine Research.|pdf=|usr=}}
{{tp|p=34276265|t=2021. New Computational Approach for Peptide Vaccine Design Against SARS-COV-2.|pdf=|usr=}}
{{tp|p=34191218|t=2021. Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines.|pdf=|usr=}}
{{tp|p=34233324|t=2021. Seropositive reaction rates of 9 B cell epitopes of the SARS-CoV-2 spike protein and the relationship between the epitopes and neutralizing antibody.|pdf=|usr=}}
{{tp|p=34226888|t=2021. China's COVID-19 vaccine approved for WHO emergency use listing.|pdf=|usr=}}
{{tp|p=34209801|t=2021. ISIDOG Consensus Guidelines on COVID-19 Vaccination for Women before, during and after Pregnancy.|pdf=|usr=}}
{{tp|p=34199053|t=2021. Systemic Adverse Events and Use of Antipyretics Predict the Neutralizing Antibody Positivity Early after the First Dose of ChAdOx1 Coronavirus Disease Vaccine.|pdf=|usr=}}
{{tp|p=34199029|t=2021. Levels of Produced Antibodies after Vaccination with mRNA Vaccine; Effect of Previous Infection with SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34202324|t=2021. Vaccine Effects on Susceptibility and Symptomatology Can Change the Optimal Allocation of COVID-19 Vaccines: South Korea as an Example.|pdf=|usr=}}
{{tp|p=34267839|t=2021. Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know?|pdf=|usr=}}
{{tp|p=34191577|t=2021. Comparing Results of Five SARS-CoV-2 Antibody Assays Before and After the First Dose of ChAdOx1 nCoV-19 Vaccine among Health Care Workers.|pdf=|usr=}}
{{tp|p=34275536|t=2021. Evolution of our understanding of MS-COVID-19 interactions and concerns for vaccination.|pdf=|usr=}}
{{tp|p=34242802|t=2021. Vaccine or monoclonal therapy: which is the winning weapon against COVID-19?|pdf=|usr=}}
{{tp|p=34326999|t=2021. COVID-19 vaccinations are associated with reduced fatality rates: Evidence from cross-county quasi-experiments.|pdf=|usr=}}
{{tp|p=34254476|t=2021. Predicted and Observed Incidence of Thromboembolic Events among Koreans Vaccinated with ChAdOx1 nCoV-19 Vaccine.|pdf=|usr=}}
{{tp|p=34254475|t=2021. Emergency Department Utilization by In-hospital Healthcare Workers after COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34243845|t=2021. Methodological Analysis: Randomized Controlled Trials for Pfizer and Moderna COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=34270752|t=2021. Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents.|pdf=|usr=}}
{{tp|p=34205301|t=2021. Antibody Response Following a Two-Dose mRNA Vaccination Regimen, in Health Care Workers of a Tertiary Hospital in Athens, Greece.|pdf=|usr=}}
{{tp|p=34236414|t=2021. Asymptomatic and Symptomatic COVID-19 Infections Among Health Care Personnel Before and After Vaccination.|pdf=|usr=}}
{{tp|p=34292295|t=2021. Incidence of Axillary Adenopathy in Breast Imaging After COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34236381|t=2021. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer.|pdf=|usr=}}
{{tp|p=34228115|t=2021. Evaluation of Messenger RNA From COVID-19 BTN162b2 and mRNA-1273 Vaccines in Human Milk.|pdf=|usr=}}
{{tp|p=34224668|t=2021. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.|pdf=|usr=}}
{{tp|p=34224667|t=2021. Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma.|pdf=|usr=}}
{{tp|p=34224666|t=2021. Blunted humoral response after mRNA vaccine in patients with haematological malignancies.|pdf=|usr=}}
{{tp|p=34312612|t=2021. Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study.|pdf=|usr=}}
{{tp|p=34258590|t=2021. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study.|pdf=|usr=}}
{{tp|p=34258589|t=2021. Impact of methotrexate on first-dose COVID-19 mRNA vaccination.|pdf=|usr=}}
{{tp|p=34250509|t=2021. Reactivation of IgA vasculitis after COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34316728|t=2021. Adult-onset Still's disease following COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34316726|t=2021. Adult-onset Still's disease after mRNA COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34326466|t=2021. Response to mRNA vaccination for COVID-19 among patients with multiple myeloma.|pdf=|usr=}}
{{tp|p=34276917|t=2021. A Rare Case of Superior Ophthalmic Vein Thrombosis and Thrombocytopenia Following ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34276916|t=2021. Immune Thrombocytopenic Purpura Cases Following COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34237049|t=2021. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.|pdf=|usr=}}
{{tp|p=34192737|t=2021. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2.|pdf=|usr=}}
{{tp|p=34219853|t=2021. Un caso de Nefritis tubulointersticial aguda despues de la vacunacion con Pfizer-BioNTech COVID-19.|pdf=|usr=}}
{{tp|p=34289075|t=2021. COVID-19 vaccination in haemodialysis patients: good things come in threes....|pdf=|usr=}}
{{tp|p=34289072|t=2021. SARS-CoV-2 vaccination in patients receiving kidney replacement therapies: where are we now with the protective immune response?|pdf=|usr=}}
{{tp|p=34245294|t=2021. Nephrotic syndrome and vasculitis following SARS-CoV-2 vaccine: true association or circumstantial?|pdf=|usr=}}
{{tp|p=34305020|t=2021. Vaccination anti-COVID-19 chez les patients dialyses et transplantes renaux.|pdf=|usr=}}
{{tp|p=34189176|t=2021. BNT162b2 Vaccine Effectiveness in Preventing Asymptomatic Infection With SARS-CoV-2 Virus: A Nationwide Historical Cohort Study.|pdf=|usr=}}
{{tp|p=34314563|t=2021. The COVID-19 vaccine and interventional procedures: Exploring the relationship between steroid administration and subsequent vaccine efficacy.|pdf=|usr=}}
{{tp|p=34313952|t=2021. Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study.|pdf=|usr=}}
{{tp|p=34239977|t=2021. Deep sequence modelling for predicting COVID-19 mRNA vaccine degradation.|pdf=|usr=}}
{{tp|p=34316263|t=2021. NICE to publish guidelines for rare blood clotting syndrome from COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34220197|t=2021. Pfizer COVID-19 vaccine recommended for pregnant women in Australia and New Zealand.|pdf=|usr=}}
{{tp|p=34276271|t=2021. Pravention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und "coronavirus disease 2019".|pdf=|usr=}}
{{tp|p=34193524|t=2021. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy.|pdf=|usr=}}
{{tp|p=34284878|t=2021. Effect of SARS-CoV-2 vaccination among health care workers in a geriatric care unit after a B.1.1.7-variant outbreak.|pdf=|usr=}}
{{tp|p=34230759|t=2021. Detection of an appropriate pharmaceutical company to get a suitable vaccine against COVID-19 with minimum cost under the quality control process.|pdf=|usr=}}
{{tp|p=34305033|t=2021. SARS-CoV-2 vaccination and metabolic radionuclide therapy: Document of the SEMNIM Endocrinology Working Group.|pdf=|usr=}}
{{tp|p=34286893|t=2021. Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies.|pdf=|usr=}}
{{tp|p=34197678|t=2021. Vaccine-induced immune thrombotic thrombocytopenia after vaccination against Covid-19: A clinical dilemma for clinicians and patients.|pdf=|usr=}}
{{tp|p=34249121|t=2021. Dealing with perceptions related to thrombosis and COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=34305424|t=2021. Covid-19 Vaccine Surveillance in Saudi Arabia: Opportunities for Real-time Assessment.|pdf=|usr=}}
{{tp|p=34267221|t=2021. A sub-national real-time epidemiological and vaccination database for the COVID-19 pandemic in Canada.|pdf=|usr=}}
{{tp|p=34234098|t=2021. Catch-as-catch-can: mRNA vaccination boosts immune responses to SARS-CoV-2 variants.|pdf=|usr=}}
{{tp|p=34274941|t=2021. A bivalent recombinant vaccine: a promising strategy against both SARS-CoV-2 variants and wild type of the virus.|pdf=|usr=}}
{{tp|p=34267185|t=2021. Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials.|pdf=|usr=}}
{{tp|p=34304601|t=2021. Cerebral Vein Thrombosis With Vaccine-Induced Immune Thrombotic Thrombocytopenia.|pdf=|usr=}}
{{tp|p=34244449|t=2021. Successful management of vaccine-induced immune thrombotic thrombocytopenia-related cerebral sinus venous thrombosis after ChAdOx1 nCov-19 vaccination.|pdf=|usr=}}
{{tp|p=34272069|t=2021. Eruption eczematiforme apres le vaccin par Pfizer-BioNTech COVID-19.|pdf=|usr=}}
{{tp|p=34238585|t=2021. COVID-19 vaccines and pregnancy: What do we know?|pdf=|usr=}}
{{tp|p=34238706|t=2021. Blood donor deferral periods after COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34406140|t=2021. SARS-CoV-2 Immunization in Patients With Inflammatory Bowel Disease May Result in Disease Flares.|pdf=|usr=}}
{{tp|p=34404083|t=2021. COVID-19 Vaccine for Chronic Gastroenterology and Hepatology Patients: A Need for Better Evidence.|pdf=|usr=}}
{{tp|p=34446440|t=2021. Initial experience of the safety and tolerability of the BNT162b2 (Pfizer-Bio-N-Tech) vaccine in extremely vulnerable children aged 12-15 years.|pdf=|usr=}}
{{tp|p=34346185|t=2021. Disease Flare and Reactogenicity in Patients with Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination.|pdf=|usr=}}
{{tp|p=34373256|t=2021. Transparency of COVID-19 vaccine trials: decisions without data.|pdf=|usr=}}
{{tp|p=34423463|t=2021. A case of acute necrotising pancreatitis following the second dose of Pfizer-BioNTech COVID-19 mRNA vaccine.|pdf=|usr=}}
{{tp|p=34427487|t=2021. Detection of SARS-CoV-2-Specific IgA in the Human Milk of COVID-19 Vaccinated Lactating Health Care Workers.|pdf=|usr=}}
{{tp|p=34424542|t=2021. Ongoing research examines COVID-19 vaccination effectiveness in patients with cancer and survivors.|pdf=|usr=}}
{{tp|p=34227767|t=2021. COVID-19 Immunity to Vaccination in India.|pdf=|usr=}}
{{tp|p=34225251|t=2021. Auto-immune hepatitis following COVID vaccination.|pdf=|usr=}}
{{tp|p=34219684|t=2021. Determining the frequency of serious adverse reactions of inactive SARS-COV-2 vaccine.|pdf=|usr=}}

{{tp|p=34191300|t=2021. COVID-19 vaccines - the way forward.|pdf=|usr=}}
{{tp|p=34286856|t=2021. Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsort-19 study.|pdf=|usr=}}
{{tp|p=34245591|t=2021. A bird's eye view on the role of dendritic cells in SARS-CoV-2 infection: Perspectives for immune-based vaccines.|pdf=|usr=}}
{{tp|p=34251905|t=2021. The Case for Mandating COVID-19 Vaccines for Health Care Workers.|pdf=|usr=}}
{{tp|p=34280332|t=2021. SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting.|pdf=|usr=}}
{{tp|p=34285048|t=2021. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.|pdf=|usr=}}
{{tp|p=34235643|t=2021. Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=34196506|t=2021. Brief Report: Humoral and cellular immune responses to SARS-CoV-2 infection and vaccination in B cell depleted autoimmune patients.|pdf=|usr=}}
{{tp|p=34196469|t=2021. A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2-vaccine - a case report.|pdf=|usr=}}
{{tp|p=34276817|t=2021. Advances of mRNA vaccines for COVID-19: A new prophylactic revolution begins.|pdf=|usr=}}
{{tp|p=34228815|t=2021. Primary cutaneous anaplastic large-cell lymphoma with marked spontaneous regression of organ manifestation after SARS-CoV-2 vaccination.|pdf=|usr=}}
{{tp|p=34281357|t=2021. Myocarditis With COVID-19 mRNA Vaccines.|pdf=|usr=}}
{{tp|p=34341683|t=2021. Seroconversion after COVID-19 vaccine in a dialysis patient on immunosuppressants.|pdf=|usr=}}
{{tp|p=34384875|t=2021. COVID-19 vaccination in Israel.|pdf=|usr=}}
{{tp|p=34418708|t=2021. Guillain-Barre syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?|pdf=|usr=}}
{{tp|p=34190859|t=2021. CoronaVac can induce the production of anti-SARS-CoV-2 IgA antibodies in human milk.|pdf=|usr=}}
{{tp|p=34226271|t=2021. Ischemie d'un membre et thrombose de l'artere pulmonaire apres l'administration du vaccin ChAdOx1 nCoV-19 (Oxford-AstraZeneca) : un cas de thrombocytopenie thrombotique immunitaire induite par le vaccin.|pdf=|usr=}}
{{tp|p=34330017|t=2021. COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=34232548|t=2021. COVID-19 vaccines: What dermatologists should know?|pdf=|usr=}}
{{tp|p=34232544|t=2021. The initial experience of COVID-19 vaccination in autoimmune blistering diseases patients from a reference care center in Italy.|pdf=|usr=}}
{{tp|p=34231301|t=2021. Exacerbation of psoriasis following COVID-19 vaccination in a patient previously treated with PD-1 inhibitor.|pdf=|usr=}}
{{tp|p=34410574|t=2021. COVID-19 Vaccination in Patients with Inflammatory Bowel Disease: A Survey from China.|pdf=|usr=}}
{{tp|p=34393073|t=2021. Clinical update on the efficacy of anti-SARS-CoV-2 mRNA vaccines in patients on the waiting list for liver transplantation and in liver transplant recipients.|pdf=|usr=}}
{{tp|p=34332100|t=2021. Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management.|pdf=|usr=}}
{{tp|p=34347278|t=2021. Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report.|pdf=|usr=}}
{{tp|p=34351606|t=2021. Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34366660|t=2021. Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems.|pdf=|usr=}}
{{tp|p=34374333|t=2021. Pityriasis Rosea as a Possible Complication of Vaccination Against COVID-19.|pdf=|usr=}}
{{tp|p=34454402|t=2021. Vaccine against SARS-CoV-2 in previously infected health care workers.|pdf=|usr=}}
{{tp|p=34454401|t=2021. Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis.|pdf=|usr=}}
{{tp|p=34391096|t=2021. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.|pdf=|usr=}}
{{tp|p=34391088|t=2021. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34391087|t=2021. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.|pdf=|usr=}}
{{tp|p=34414368|t=2021. Safety and immunogenicity of a QazCovid-in(R) inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan.|pdf=|usr=}}
{{tp|p=34459725|t=2021. Fatal Systemic Capillary Leak Syndrome after SARS-CoV-2Vaccination in Patient with Multiple Myeloma.|pdf=|usr=}}
{{tp|p=34427172|t=2021. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies.|pdf=|usr=}}
{{tp|p=34365904|t=2021. Live attenuated coronavirus vaccines deficient in N7-Methyltransferase activity induce both humoral and cellular immune responses in mice.|pdf=|usr=}}
{{tp|p=34399446|t=2021. COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society.|pdf=|usr=}}
{{tp|p=34334861|t=2021. EVOLUCION DE LOS CASOS DE TOS FERINA TRAS LA VACUNACION DE LA EMBARAZADA Y LA PANDEMIA COVID-19.|pdf=|usr=}}
{{tp|p=34334860|t=2021. Effectiveness of the BNT162b2 mRNA Covid-19 Vaccine in Spanish Healthcare Workers.|pdf=|usr=}}
{{tp|p=34457370|t=2021. A vaccine based on the receptor-binding domain of the spike protein expressed in glycoengineered Pichia pastoris targeting SARS-CoV-2 stimulates neutralizing and protective antibody responses.|pdf=|usr=}}
{{tp|p=34405870|t=2021. Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia.|pdf=|usr=}}
{{tp|p=34254358|t=2021. Participation in ENSEMBLE phase III multicenter clinical trial of Ad26.CoV2.S, a COVID-19 vaccine: An investigational drug services perspective.|pdf=|usr=}}
{{tp|p=34363731|t=2021. Pityriasis rosea following SARS-CoV-2 vaccination: A case series.|pdf=|usr=}}
{{tp|p=34292611|t=2021. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34370344|t=2021. Cutaneous reactions following CoronaVac COVID-19 vaccination: a case series of six healthcare workers from a single centre.|pdf=|usr=}}
{{tp|p=34363717|t=2021. Herpes zoster after ChAdOx1 nCoV-19 vaccine: a case series.|pdf=|usr=}}
{{tp|p=34363713|t=2021. Cutaneous reactions to inactivated SARS-CoV-2 vaccine and ChAdOx1-S (recombinant) vaccine against SARS-CoV-2: a case series from the Philippines.|pdf=|usr=}}
{{tp|p=34363647|t=2021. Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre.|pdf=|usr=}}
{{tp|p=34363637|t=2021. Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature.|pdf=|usr=}}
{{tp|p=34363258|t=2021. Three cases of vesiculobullous non-IgE-mediated cutaneous reactions to tozinameran (Pfizer-BioNTech COVID-19 vaccine).|pdf=|usr=}}
{{tp|p=34363257|t=2021. Herpes zoster after inactivated SARS-CoV-2 vaccine in two healthy young adults.|pdf=|usr=}}
{{tp|p=34416058|t=2021. A Bullous Eruption following the Pfizer-BioNTech COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34296443|t=2021. Effectiveness of COVID-19 vaccines: findings from real world studies.|pdf=|usr=}}
{{tp|p=34368991|t=2021. Severe Dyskinesia After Administration of SARS-CoV2 mRNA Vaccine in Parkinson's Disease.|pdf=|usr=}}
{{tp|p=34279842|t=2021. The Worldwide Effort to Develop Vaccines for COVID-19.|pdf=|usr=}}
{{tp|p=34259040|t=2021. FDG-Avid Ipsilateral Iliac and Inguinal Lymphadenopathy After COVID-19 Vaccination With Thigh Injection.|pdf=|usr=}}
{{tp|p=34187985|t=2021. Gastroparesis After Pfizer-BioNTech COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34272251|t=2021. Response to: 'Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'' by Westhoff et al.|pdf=|usr=}}
{{tp|p=34187777|t=2021. Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'.|pdf=|usr=}}
{{tp|p=34210672|t=2021. Covid-19: Pfizer vaccine could provide lasting immunity, small study suggests.|pdf=|usr=}}
{{tp|p=34366403|t=2021. Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines.|pdf=|usr=}}
{{tp|p=34433191|t=2021. The impact of COVID-19 in pregnancy: Part II. Vaccination to pregnant women.|pdf=|usr=}}
{{tp|p=34301797|t=2021. Haemophagocytic lymphohistiocytosis after ChAdOx1 nCoV-19 vaccination.|pdf=|usr=}}
{{tp|p=34418261|t=2021. Systemic lupus erythematosus after COVID-19 vaccination: A case report.|pdf=|usr=}}
{{tp|p=34229482|t=2021. Delayed Cutaneous Reactivity Associated With COVID-19 Vaccines Is Rare.|pdf=|usr=}}
{{tp|p=34459023|t=2021. Five Japanese cases of delayed large local reactions to coronavirus disease 2019 vaccines.|pdf=|usr=}}
{{tp|p=34284839|t=2021. COVID-19 age-dependent immunology and clinical outcomes: implications for vaccines.|pdf=|usr=}}
{{tp|p=34397201|t=2021. Herpes Zoster Following COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34459036|t=2021. Clinicopathological features of cutaneous reactions after mRNA-based COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=34416052|t=2021. Flagellate purpura associated with COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34416044|t=2021. Two cases of papulo-pustular rosacea-like eruptions following COVID-19 vaccinations.|pdf=|usr=}}
{{tp|p=34297036|t=2021. Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses.|pdf=|usr=}}
{{tp|p=34287620|t=2021. Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples.|pdf=|usr=}}
{{tp|p=34259836|t=2021. Study Suggests Lasting Immunity After COVID-19, With a Big Boost From Vaccination.|pdf=|usr=}}
{{tp|p=34251417|t=2021. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women.|pdf=|usr=}}
{{tp|p=34319363|t=2021. Association of Facial Pustular Neutrophilic Eruption With Messenger RNA-1273 SARS-CoV-2 Vaccine.|pdf=|usr=}}
{{tp|p=34254978|t=2021. Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis.|pdf=|usr=}}
{{tp|p=34309623|t=2021. Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose.|pdf=|usr=}}
{{tp|p=34432329|t=2021. Effects of the Coronavirus Disease 2019 Pandemic on Motor Symptoms in Parkinson's Disease: An Observational Study.|pdf=|usr=}}
{{tp|p=34387536|t=2021. SARS-CoV-2 antibodies in multiple sclerosis patients depending on the vaccine mode of action?|pdf=|usr=}}
{{tp|p=34379914|t=2021. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis.|pdf=|usr=}}
{{tp|p=34437789|t=2021. Audio Interview: Assessing Vaccine Safety.|pdf=|usr=}}
{{tp|p=34379932|t=2021. Audio Interview: Monoclonal Antibodies and Booster Shots.|pdf=|usr=}}
{{tp|p=34429547|t=2021. Intranasal vaccination.|pdf=|usr=}}
{{tp|p=34331051|t=2021. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.|pdf=|usr=}}
{{tp|p=34381200|t=2021. Reasons for success and lessons learnt from nanoscale vaccines against COVID-19.|pdf=|usr=}}
{{tp|p=34408308|t=2021. Antibodies reveal who's protected by Moderna's COVID vaccine.|pdf=|usr=}}
{{tp|p=34404949|t=2021. Daily briefing: Iran's home-grown COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=34429544|t=2021. COVID vaccines and blood clots: what researchers know so far.|pdf=|usr=}}
{{tp|p=34408311|t=2021. Decades-old SARS virus infection triggers potent response to COVID vaccines.|pdf=|usr=}}
{{tp|p=34404947|t=2021. Iran hopes to defeat COVID with home-grown crop of vaccines.|pdf=|usr=}}
{{tp|p=34354274|t=2021. COVID vaccine boosters: the most important questions.|pdf=|usr=}}
{{tp|p=34345036|t=2020. Daily briefing: World's largest vaccine maker bets on Oxford coronavirus candidate.|pdf=|usr=}}
{{tp|p=34376851|t=2020. Daily briefing: Russia approves 'reckless' coronavirus vaccine.|pdf=|usr=}}
{{tp|p=34346657|t=2021. Verwardheid en buikpijn na covid-19-vaccinatie.|pdf=|usr=}}
{{tp|p=34346643|t=2021. 'Vaccine-induced immune thrombotic trombocytopenia'.|pdf=|usr=}}
{{tp|p=34351716|t=2021. COVID-19-vaccins: hoe zit het?|pdf=|usr=}}
{{tp|p=34450648|t=2021. Weekly seroconversion rate of the mRNA-1273 SARS-CoV-2 vaccine in haemodialysis patients.|pdf=|usr=}}
{{tp|p=34450646|t=2021. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in a haemodialysis cohort.|pdf=|usr=}}
{{tp|p=34333995|t=2021. Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia.|pdf=|usr=}}
{{tp|p=34412144|t=2021. FDG uptake in axillaren Lymphknoten nach COVID-19 Impfung - ein Fallstrick in der Interpretation eines FDG-PET/CT bei einem Patienten mit malignem Melanom und hochgradig Metastasen-suspekten axillaren Lymphknoten.|pdf=|usr=}}
{{tp|p=34344280|t=2021. Bilateral Multifocal Choroiditis following COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34213988|t=2021. Panuveitis following Vaccination for COVID-19.|pdf=|usr=}}
{{tp|p=34406890|t=2021. COVID-19 Vaccination and Bilateral Multifocal Choroiditis.|pdf=|usr=}}
{{tp|p=34402726|t=2021. Acute Thyroiditis and Bilateral Optic Neuritis following SARS-CoV-2 Vaccination with CoronaVac: A Case Report.|pdf=|usr=}}
{{tp|p=34379565|t=2021. Acute Uveitis following COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34272340|t=2021. Important Considerations for COVID-19 Vaccination of Children With Developmental Disabilities.|pdf=|usr=}}
{{tp|p=34282971|t=2021. Myocarditis Associated with mRNA COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34310229|t=2021. Evolution of Lymphadenopathy at PET/MRI after COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=34303337|t=2021. Nanovaccine: A hope to triumph the battle against novel Coronavirus disease 2019 (COVID-19).|pdf=|usr=}}
{{tp|p=34192840|t=2021. [Rapid guideline for COVID-19 vaccination in patients with chronic liver diseases, hepatolbiliary malignancy and liver transplant].|pdf=|usr=}}

{{tp|p=34421121|t=2021. Deep survey for designing a vaccine against SARS-CoV-2 and its new mutations.|pdf=|usr=}}
{{tp|p=34356507|t=2021. Lymphadenopathy after the Anti-COVID-19 Vaccine: Multiparametric Ultrasound Findings.|pdf=|usr=}}
{{tp|p=34439984|t=2021. Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers.|pdf=|usr=}}
{{tp|p=34343897|t=2021. Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34440072|t=2021. Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults.|pdf=|usr=}}
{{tp|p=34440163|t=2021. COVID-19 Disease, Women's Predominant Non-Heparin Vaccine-Induced Thrombotic Thrombocytopenia and Kounis Syndrome: A Passepartout Cytokine Storm Interplay.|pdf=|usr=}}
{{tp|p=34440239|t=2021. Picture of the Favourable Immune Profile Induced by Anti-SARS-CoV-2 Vaccination.|pdf=|usr=}}
{{tp|p=34356644|t=2021. COVID-19 Vaccines and Thrombosis-Roadblock or Dead-End Street?|pdf=|usr=}}
{{tp|p=34339501|t=2021. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy.|pdf=|usr=}}
{{tp|p=34387648|t=2021. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma.|pdf=|usr=}}
{{tp|p=34387646|t=2021. Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies.|pdf=|usr=}}
{{tp|p=34330895|t=2021. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia.|pdf=|usr=}}
{{tp|p=34341335|t=2021. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment.|pdf=|usr=}}
{{tp|p=34376633|t=2021. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies.|pdf=|usr=}}
{{tp|p=34397451|t=2021. Subcutaneous injection of mRNA vaccines against severe acute respiratory syndrome coronavirus 2: an option for severe bleeding disorders or anticoagulated patients?|pdf=|usr=}}
{{tp|p=34348657|t=2021. Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report.|pdf=|usr=}}
{{tp|p=34420521|t=2021. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naive recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.|pdf=|usr=}}
{{tp|p=34446426|t=2021. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.|pdf=|usr=}}
{{tp|p=34417194|t=2021. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study.|pdf=|usr=}}
{{tp|p=34417165|t=2021. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.|pdf=|usr=}}
{{tp|p=34407952|t=2021. Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study.|pdf=|usr=}}
{{tp|p=34330729|t=2021. Guillain-Barre syndrome after COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34330722|t=2021. Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34348912|t=2021. Remitting seronegative symmetrical synovitis with pitting oedema following BNT162b2 mRNA COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34400433|t=2021. Extensive thrombosis after COVID-19 vaccine: cause or coincidence?|pdf=|usr=}}
{{tp|p=34405142|t=2021. Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study.|pdf=|usr=}}
{{tp|p=34396084|t=2021. SARS CoV2 vaccine and aphasia.|pdf=|usr=}}
{{tp|p=34456555|t=2021. A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population.|pdf=|usr=}}
{{tp|p=34375696|t=2021. Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers.|pdf=|usr=}}
{{tp|p=34450047|t=2021. Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer.|pdf=|usr=}}
{{tp|p=34348121|t=2021. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.|pdf=|usr=}}
{{tp|p=34331856|t=2021. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies.|pdf=|usr=}}
{{tp|p=34359701|t=2021. Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment.|pdf=|usr=}}
{{tp|p=34439346|t=2021. Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs.|pdf=|usr=}}
{{tp|p=34420869|t=2021. Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review.|pdf=|usr=}}
{{tp|p=34395000|t=2021. Oxford-AstraZeneca Coronavirus Disease-2019 Vaccine-Induced Immune Thrombocytopenia on Day Two.|pdf=|usr=}}
{{tp|p=34344867|t=2021. Thromboembolism after COVID-19 vaccine in patients with preexisting thrombocytopenia.|pdf=|usr=}}
{{tp|p=34408130|t=2021. Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=34400614|t=2021. Humoral responses in naive or SARS-CoV-2 experienced individuals vaccinated with an inactivated vaccine.|pdf=|usr=}}
{{tp|p=34400612|t=2021. Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy.|pdf=|usr=}}
{{tp|p=34373443|t=2021. Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization.|pdf=|usr=}}
{{tp|p=34428428|t=2021. An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates.|pdf=|usr=}}
{{tp|p=34450033|t=2021. Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34411541|t=2021. Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals.|pdf=|usr=}}
{{tp|p=34390647|t=2021. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals.|pdf=|usr=}}
{{tp|p=34352226|t=2021. Systemic IL-15, IFN-gamma, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients.|pdf=|usr=}}
{{tp|p=34341489|t=2021. Time of day influences immune response to an inactivated vaccine against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34440721|t=2021. Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination.|pdf=|usr=}}
{{tp|p=34440710|t=2021. Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers.|pdf=|usr=}}
{{tp|p=34407651|t=2021. Incidence of headache after COVID-19 vaccination in patients with history of headache: A cross-sectional study.|pdf=|usr=}}
{{tp|p=34356586|t=2021. Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far?|pdf=|usr=}}
{{tp|p=34414339|t=2021. Intense Emotional Stress Over Potential Coronavirus Disease Vaccination Side Effects Leads to Takotsubo Cardiomyopathy.|pdf=|usr=}}
{{tp|p=34429981|t=2021. Rituximab-induced acute lympholysis and pancytopenia after COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34358295|t=2021. Poor Humoral Response in Solid Organ Transplant Recipients following Complete mRNA SARS-CoV-2 Vaccination.|pdf=|usr=}}
{{tp|p=34358373|t=2021. ChAdOx1 SARS-CoV-2 vaccination: A putative precipitant of adrenal crises.|pdf=|usr=}}
{{tp|p=34415637|t=2021. Allergic and cutaneous reactions following inactivated SARS-CoV-2 vaccine (CoronaVac((R)) ) in healthcare workers.|pdf=|usr=}}
{{tp|p=34399001|t=2021. Symmetrical drug-related intertriginous and flexural exanthema like eruption associated with COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34398977|t=2021. De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34379821|t=2021. Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34340203|t=2021. Mammographic and sonographic findings in the breast and axillary tail following a COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34358692|t=2021. Guillain-Barre syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34363462|t=2021. Determining the Incidence of Asymptomatic SARS-CoV-2 among Early Recipients of COVID-19 Vaccines: A Prospective Cohort Study of Healthcare Workers before, during and after Vaccination [DISCOVER-COVID-19].|pdf=|usr=}}
{{tp|p=34358310|t=2021. Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States.|pdf=|usr=}}
{{tp|p=34460902|t=2021. Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada.|pdf=|usr=}}
{{tp|p=34343259|t=2021. Differential anti-S antibody titers in vaccinated residents during an outbreak of SARS-CoV-2 variant B.1.351 (beta) in an elderly nursing home.|pdf=|usr=}}
{{tp|p=34410361|t=2021. Post-vaccination COVID-19: A case-control study and genomic analysis of 119 breakthrough infections in partially vaccinated individuals.|pdf=|usr=}}
{{tp|p=34406358|t=2021. Intravenous injection of COVID-19 mRNA vaccine can induce acute myopericarditis in mouse model.|pdf=|usr=}}
{{tp|p=34383902|t=2021. Heterologous ChAdOx1-S/BNT162b2 vaccination: neutralizing antibody response to SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34429940|t=2021. Vaccination against COVID-19 in a haemodialysis centre: what is the risk of bleeding complications?|pdf=|usr=}}
{{tp|p=34371204|t=2021. Both SARS-CoV-2 infection and vaccination in pregnancy elicited neutralizing antibodies in pregnant women and newborns.|pdf=|usr=}}
{{tp|p=34375755|t=2021. Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan.|pdf=|usr=}}
{{tp|p=34438069|t=2021. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1.|pdf=|usr=}}
{{tp|p=34428593|t=2021. Which are the best coronavirus disease 2019 vaccines?|pdf=|usr=}}
{{tp|p=34391930|t=2021. Precautions after vaccinating immunosuppressed patients with mRNA-based vaccines against SARS-CoV-2: does one size fit all?|pdf=|usr=}}
{{tp|p=34414880|t=2021. Reports of anaphylaxis after coronavirus disease 2019 vaccination, South Korea, 26 February to 30 April 2021.|pdf=|usr=}}
{{tp|p=34355689|t=2021. Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021.|pdf=|usr=}}
{{tp|p=34383900|t=2021. Brugada syndrome and COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=34365880|t=2021. Sars-Cov-2 virus and vaccination; biological and statistical framework.|pdf=|usr=}}
{{tp|p=34415818|t=2021. To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination.|pdf=|usr=}}
{{tp|p=34338126|t=2021. COVID-19 vaccines approved in the European Union: current evidence and perspectives.|pdf=|usr=}}
{{tp|p=34426655|t=2021. Corneal graft rejection following COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34331769|t=2021. Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice.|pdf=|usr=}}
{{tp|p=34386486|t=2021. Development and Delivery Systems of mRNA Vaccines.|pdf=|usr=}}
{{tp|p=34447374|t=2021. COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial.|pdf=|usr=}}
{{tp|p=34386018|t=2021. HLA Does Not Impact on Short-Medium-Term Antibody Response to Preventive Anti-SARS-Cov-2 Vaccine.|pdf=|usr=}}
{{tp|p=34368197|t=2021. Case Report: Infection With SARS-CoV-2 in the Presence of High Levels of Vaccine-Induced Neutralizing Antibody Responses.|pdf=|usr=}}
{{tp|p=34427272|t=2021. Facial nerve palsy after COVID-19 vaccination - A rare association or a coincidence.|pdf=|usr=}}
{{tp|p=34427638|t=2021. Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients.|pdf=|usr=}}
{{tp|p=34363344|t=2021. Arthritis of the left elbow joint after vaccination against SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=34350721|t=2021. A vaccination update for rheumatologists-SARS-CoV-2, influenza and herpes zoster.|pdf=|usr=}}
{{tp|p=34431530|t=2021. COVID-19 vaccination and exanthema-like eruption.|pdf=|usr=}}
{{tp|p=34453510|t=2021. Insights from a murine model of COVID-19 mRNA vaccination-induced myopericarditis: Could accidental intravenous vaccine injection induce myopericarditis?|pdf=|usr=}}
{{tp|p=34355678|t=2021. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=34334663|t=2021. Anaphylaxis and Coronavirus Disease 2019 vaccine: a danger relationship?|pdf=|usr=}}
{{tp|p=34455671|t=2021. Subacute cutaneous lupus erythematosus flare triggered by COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34427024|t=2021. Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID-19 vaccines: A report of two cases.|pdf=|usr=}}
{{tp|p=34432391|t=2021. COVID-19 post-vaccination lymphadenopathy: Report of cytological findings from fine needle aspiration biopsy.|pdf=|usr=}}
{{tp|p=34391596|t=2021. Effectiveness of the BNT162b2 mRNA Covid-19 vaccine in Spanish healthcare workers.|pdf=|usr=}}
{{tp|p=34344559|t=2021. Sindrome de Ramsay Hunt tras vacunacion con m-RNA SARS-COV-2.|pdf=|usr=}}
{{tp|p=34399868|t=2021. SARS-CoV-2 Immunogenicity in individuals infected before and after COVID-19 vaccination: Israel, January-March 2021.|pdf=|usr=}}
{{tp|p=34355379|t=2021. Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: a report of an autoptic case and review of the literature.|pdf=|usr=}}
{{tp|p=34357839|t=2021. Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents.|pdf=|usr=}}
{{tp|p=34192777|t=2021. COVID-19: SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia.|pdf=|usr=}}
{{tp|p=34413252|t=2021. Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: preliminary results.|pdf=|usr=}}
{{tp|p=34347563|t=2021. Electromyoneurography and laboratory findings in a case of Guillain-Barre syndrome after second dose of Pfizer COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34435935|t=2021. Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34406914|t=2021. Protecting adults at risk of pneumococcal infection and influenza from exposure to SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34348908|t=2021. Immunogenicity of SARS-CoV-2 Vaccine in Dialysis.|pdf=|usr=}}
{{tp|p=34382563|t=2021. Considerations for COVID-19 vaccination in pregnancy.|pdf=|usr=}}
{{tp|p=34382561|t=2021. Recommendations for the diagnosis and management of vaccine-induced immune thrombotic thrombocytopenia.|pdf=|usr=}}
{{tp|p=34382557|t=2021. The J&J COVID-19 vaccine: Fit for purpose in our setting.|pdf=|usr=}}
{{tp|p=34376569|t=2021. Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection.|pdf=|usr=}}

{{tp|p=34333695|t=2021. Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis?|pdf=|usr=}}
{{tp|p=34331522|t=2021. Patients with suspected allergic reactions to COVID-19 vaccines can be safely revaccinated after diagnostic work-up.|pdf=|usr=}}
{{tp|p=34408875|t=2021. Rapid whole-blood assay to detect SARS-CoV-2-specific memory T-cell immunity following a single dose of AstraZeneca ChAdOx1-S COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34362727|t=2021. Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford-AstraZeneca) vaccination.|pdf=|usr=}}
{{tp|p=34344774|t=2021. Bacillus Calmette-Guerin scar flare after an mRNA SARS-CoV-2 vaccine.|pdf=|usr=}}
{{tp|p=34381159|t=2021. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration.|pdf=|usr=}}
{{tp|p=34352457|t=2021. An in-depth in silico and immunoinformatics approach for designing a potential multi-epitope construct for the effective development of vaccine to combat against SARS-CoV-2 encompassing variants of concern and interest.|pdf=|usr=}}
{{tp|p=34331834|t=2021. Application of quantitative systems pharmacology to guide the optimal dosing of COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=34336436|t=2021. Bell's Palsy After 24 Hours of mRNA-1273 SARS-CoV-2 Vaccine.|pdf=|usr=}}
{{tp|p=34458035|t=2021. SARS-CoV-2 Vaccination-Induced Transverse Myelitis.|pdf=|usr=}}
{{tp|p=34447649|t=2021. Thrombotic Thrombocytopenic Purpura Presentation in an Elderly Gentleman Following COVID Vaccine Circumstances.|pdf=|usr=}}
{{tp|p=34447646|t=2021. Facial Diplegia: A Rare, Atypical Variant of Guillain-Barre Syndrome and Ad26.COV2.S Vaccine.|pdf=|usr=}}
{{tp|p=34447639|t=2021. Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination.|pdf=|usr=}}
{{tp|p=34430106|t=2021. Drug-Induced Liver Injury After COVID-19 Vaccine.|pdf=|usr=}}
{{tp|p=34408937|t=2021. A COVID-Positive 52-Year-Old Man Presented With Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson & Johnson Vaccination: A Case-Study.|pdf=|usr=}}
{{tp|p=34367780|t=2021. Two Cases of Post-Moderna COVID-19 Vaccine Encephalopathy Associated With Nonconvulsive Status Epilepticus.|pdf=|usr=}}
{{tp|p=34367770|t=2021. Epidemiological Study of COVID-19 Fatalities and Vaccine Uptake: Insight From a Public Health Database in Ontario, Canada.|pdf=|usr=}}
{{tp|p=34369046|t=2021. COVID-19 vaccine-induced urticarial vasculitis.|pdf=|usr=}}
{{tp|p=34350668|t=2021. Onset/flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine (Oxford-AstraZeneca/Covishield): Report of two cases.|pdf=|usr=}}
{{tp|p=34364299|t=2021. Evaluation of the dose-effect association between the number of doses and duration since the last dose of COVID-19 vaccine, and its efficacy in preventing the disease and reducing disease severity: A single centre, cross-sectional analytical study from India.|pdf=|usr=}}
{{tp|p=34450248|t=2021. Short-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes.|pdf=|usr=}}
{{tp|p=34332306|t=2021. Serological response in health care workers after a single dose of SARS-CoV-2 vaccine using six automated SARS-CoV-2 antibody assays.|pdf=|usr=}}
{{tp|p=34400057|t=2021. COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.|pdf=|usr=}}
{{tp|p=34438245|t=2021. Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population.|pdf=|usr=}}
{{tp|p=34428684|t=2021. Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix.|pdf=|usr=}}
{{tp|p=34337738|t=2021. Serum antibody response to BNT162b2 after natural SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=34363519|t=2021. Hypertension and Covid-19 vaccines: are there any differences between the different vaccines? A safety signal.|pdf=|usr=}}
{{tp|p=34419309|t=2021. ChAdOx1 nCoV-19 effectiveness during an unprecedented surge in SARS COV-2 infections.|pdf=|usr=}}
{{tp|p=34433495|t=2021. Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: a rare clinical reaction.|pdf=|usr=}}
{{tp|p=34447349|t=2021. Severe Multiple Sclerosis Relapse After COVID-19 Vaccination: A Case Report.|pdf=|usr=}}
{{tp|p=34393988|t=2021. Vaccine Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis With High Fatality Rate: A Case Series.|pdf=|usr=}}
{{tp|p=34414110|t=2021. Interference of COVID-19 Vaccination With PET/CT Leads to Unnecessary Additional Imaging in a Patient With Metastatic Cutaneous Melanoma-Case Report.|pdf=|usr=}}
{{tp|p=34352148|t=2021. Immunity to SARS-CoV-2 induced by infection or vaccination.|pdf=|usr=}}
{{tp|p=34397348|t=2021. Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Greek healthcare workers.|pdf=|usr=}}
{{tp|p=34453830|t=2021. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients.|pdf=|usr=}}
{{tp|p=34353858|t=2021. Vaccination and multiple sclerosis in the era of the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=34412098|t=2021. Anti-SARS-CoV-2 IgA Response in Baseline Seronegative and Seropositive Recipients of BNT162b2 mRNA COVID-19 Vaccine.|pdf=|usr=}}
{{tp|p=34332972|t=2021. Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents.|pdf=|usr=}}
{{tp|p=34379509|t=2021. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters.|pdf=|usr=}}
{{tp|p=34407309|t=2021. Antibody Response to Severe Acute Respiratory Syndrome-Coronavirus-2 Messenger RNA Vaccines in Liver Transplant Recipients.|pdf=|usr=}}
{{tp|p=34398511|t=2021. Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase.|pdf=|usr=}}
{{tp|p=34331506|t=2021. Thrombocytopenia in a teen with sickle cell disease following COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34411407|t=2021. Comment on: Thrombocytopenia in a teen with sickle cell disease following COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34432063|t=2021. ChAdOx1 COVID-19 vaccine-induced thrombocytopenia syndrome.|pdf=|usr=}}
{{tp|p=34432055|t=2021. Myeloperoxidase Anti-neutrophil Cytoplasmic Antibody Positive Optic Perineuritis after mRNA Coronavirus Disease-19 Vaccine: A Case Report.|pdf=|usr=}}
{{tp|p=34402669|t=2021. Parsonage-Turner Syndrome Following COVID-19 Vaccination: MR Neurography.|pdf=|usr=}}
{{tp|p=34402666|t=2021. Imaging and Hematologic Findings in Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 (AstraZeneca) Vaccination.|pdf=|usr=}}
{{tp|p=34387243|t=2021. Immune Response Post-SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Receiving Belatacept.|pdf=|usr=}}
{{tp|p=34381004|t=2021. Serological Response to the BNT162b2 COVID-19 mRNA Vaccine in Adolescent and Young Adult Kidney Transplant Recipients.|pdf=|usr=}}
{{tp|p=34342963|t=2021. Cellular and Humoral Immune Responses After 3 Doses of BNT162b2 mRNA SARS-CoV-2 Vaccine in Kidney Transplant.|pdf=|usr=}}
{{tp|p=34455752|t=2021. [SARS-CoV-2 vaccines induced immune thrombotic thrombocytopenia].|pdf=|usr=}}
{{tp|p=34406398|t=2021. Interpreting prevention of COVID-19 and vaccines.|pdf=|usr=}}
{{tp|p=34427924|t=2021. The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older.|pdf=|usr=}}
{{tp|p=34453849|t=2021. COVID-19 Vaccine among Actively-Treated People with Cancer: A Glimpse into the Known Unknowns?|pdf=|usr=}}
{{tp|p=34453841|t=2021. Prioritizing Cancer Patients for Vaccination in India.|pdf=|usr=}}
{{tp|p=34362855|t=2021. Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder.|pdf=|usr=}}
{{tp|p=34341144|t=2021. What should we do about vaccination of patients on anti-CD20 antibody therapy?|pdf=|usr=}}
{{tp|p=34408003|t=2021. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis.|pdf=|usr=}}
{{tp|p=34369471|t=2021. Transient Oculomotor Palsy Following the Administration of the Messenger RNA-1273 Vaccine for SARS-CoV-2 Diplopia Following the COVID-19 Vaccine.|pdf=|usr=}}
{{tp|p=34420249|t=2021. Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination.|pdf=|usr=}}
{{tp|p=34347673|t=2021. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination for Paediatric Patients With Inflammatory Bowel Diseases.|pdf=|usr=}}
{{tp|p=34347001|t=2021. Myocarditis and Pericarditis After Vaccination for COVID-19.|pdf=|usr=}}
{{tp|p=34459863|t=2021. Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273.|pdf=|usr=}}
{{tp|p=34374737|t=2021. Oldest Adults Need 2 mRNA Vaccine Doses to Neutralize SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34374736|t=2021. COVID-19 mRNA Vaccines Blunt Breakthrough Infection Severity.|pdf=|usr=}}
{{tp|p=34374740|t=2021. Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children.|pdf=|usr=}}
{{tp|p=34374713|t=2021. Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review.|pdf=|usr=}}
{{tp|p=34398185|t=2021. Caution in Interpreting Facial Paralysis Data to Understand COVID-19 Vaccination Risks.|pdf=|usr=}}
{{tp|p=34398177|t=2021. Caution in Interpreting Facial Paralysis Data to Understand COVID-19 Vaccination Risks-Reply.|pdf=|usr=}}
{{tp|p=34379085|t=2021. Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease.|pdf=|usr=}}
{{tp|p=34431208|t=2021. Guillain-Barre syndrome after COVID-19 mRNA vaccination in a liver transplant recipient with favorable treatment response.|pdf=|usr=}}
{{tp|p=34416086|t=2021. New-Onset Antibodies to Platelet Factor 4 Following Liver Transplantation From a Donor With Vaccine-Induced Thrombotic Thrombocytopenia.|pdf=|usr=}}
{{tp|p=34408089|t=2021. SARS-CoV-2 Antibodies in Breast Milk After Vaccination.|pdf=|usr=}}
{{tp|p=34389692|t=2021. COVID-19 Vaccination-Associated Myocarditis in Adolescents.|pdf=|usr=}}
{{tp|p=34362856|t=2021. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions.|pdf=|usr=}}
{{tp|p=34446449|t=2021. Acute immune thrombocytopenic purpura post first dose of COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34446448|t=2021. Multisystem inflammatory syndrome after SARS-CoV-2 vaccination (MIS-V), to interpret with caution.|pdf=|usr=}}
{{tp|p=34347105|t=2021. Neuralgic amyotrophy following COVID-19 mRNA vaccination.|pdf=|usr=}}
{{tp|p=34450645|t=2021. Emergence of new onset SLE following SARS-CoV-2 vaccination.|pdf=|usr=}}
{{tp|p=34415336|t=2021. IgA nephropathy flare-up following SARS-CoV-2 vaccination.|pdf=|usr=}}
{{tp|p=34369440|t=2021. Uveitis following the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: a possible association.|pdf=|usr=}}
{{tp|p=34373413|t=2021. [Cerebral vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination].|pdf=|usr=}}
{{tp|p=34385356|t=2021. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.|pdf=|usr=}}
{{tp|p=34362838|t=2021. COVID-19 vaccine-related interstitial lung disease: a case study.|pdf=|usr=}}
{{tp|p=34352912|t=2021. Modeling the Effects of Intravasal Administration of AstraZeneca ChAdOx1 nCoV-19 Vaccine on Human Platelets.|pdf=|usr=}}
{{tp|p=34352911|t=2021. Autoimmunity after Coronavirus Disease 2019 (COVID-19) Vaccine: A Case of Acquired Hemophilia A.|pdf=|usr=}}
{{tp|p=34388849|t=2021. Platelet Surface Protein Expression and Reactivity upon TRAP Stimulation after BNT162b2 Vaccination.|pdf=|usr=}}
{{tp|p=34450686|t=2021. SARS-CoV-2 vaccination in solid-organ transplant recipients: What the clinician needs to know.|pdf=|usr=}}
{{tp|p=34456266|t=2021. Preemptive Antibody Therapy for Vaccine Breakthrough SARS-CoV-2 Infection in Immunocompromised Patients.|pdf=|usr=}}
{{tp|p=34428188|t=2021. Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.|pdf=|usr=}}
{{tp|p=34406187|t=2021. SARS-CoV-2 Infection After Full Vaccination in Kidney Transplant Recipients.|pdf=|usr=}}
{{tp|p=34356021|t=2021. [SARS-CoV-2 vaccine-induced immune thrombosis and thrombocytopenia].|pdf=|usr=}}